

## HEADLINES

### **Fifth Annual Biomedical Research Symposium “Image-Guided Therapy”**

Wednesday, November 12, 2008

8:30 AM - 6:00 PM

Biomedical Science Research Building (BSRB) Auditorium

The Fifth Annual Biomedical Research Symposium will take place on November 12, 2008. This year's topic is "Image-Guided Therapy." A goal of this yearly symposium, jointly sponsored by the Medical School Office of Research and Biomedical Engineering, is to foster networks and collaborations within and outside the University in topics at the forefront of science and medicine. This year's symposium will focus on advances that integrate imaging into various therapeutic procedures. Participants will learn about new research findings in the imaging sciences, molecular imaging, and clinical systems for image-guided therapy. Internationally recognized experts will address these topics, and describe the challenges and opportunities that lie in cross-disciplinary research and clinical developments. This symposium will be of particular interest to faculty and students who study fundamental aspects of imaging systems, molecular imaging methods, and especially those who practice and/or investigate methods of therapy that currently involve imaging or which could benefit from improved mechanisms to stage, guide, and/or assess therapeutic impact. Researchers at U-M are invited to present their work at a poster session.

- **Call for Abstracts**

- **Extended Deadline: October 17, 2008**

- (Extended from October 9, 2008)

- The Office of Research is soliciting abstracts for this symposium. Abstracts from a broad range of interrelated topics and disciplines will be selected for the poster presentation. The abstracts must be limited to 250 words and include the title. For each author, list at least their name, department or division, and institution. Registration for the symposium is required in order to submit an abstract. To register and submit an abstract for the symposium, go to (<http://www.med.umich.edu/medschool/research/symposiums/2008>).

- **Registration**

- **Deadline: October 22, 2008**

- To attend the symposium, please register online at (<http://www.med.umich.edu/medschool/research/symposiums/2008>).

- **CME Accreditation**

- The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical

education for physicians. The University of Michigan Medical School designates this educational activity for a maximum of 6 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact Kathryn Ridner at ([kridner@umich.edu](mailto:kridner@umich.edu)) or 734-763-4086 with questions.

### **Cassandra Wong Appointed New BRCF Director**

The Office of Research is pleased to announce the appointment of Cassandra Wong as the new Biomedical Research Core Facilities (BRCF) Director. Most recently, Ms. Wong has been serving as the Interim Director of BRCF. Previously she was the Director of the Biomedical Research Store where her responsibilities included (1) evaluating and creating financial, personnel and operating models, new business opportunities and plans for expansion; (2) determining long-range and short-term financial budgets, financial analyses and metrics, cost recovery rates and (3) overseeing, evaluating and optimizing operational areas, including customer service, vendor programs and relations, financial transactions and reconciliation, inventory control, space usage, and compliance with applicable OSEH and federal regulations. Her recent accomplishments include the creation of the first campus-wide onsite tax-free ethanol program at the University, completed within three months due to closure of M-Stores and the establishment of a third store site at A681 BSRB. Revenue from this site by the end of FY2008 is projected at over \$700,000 from 200 square feet of space.

Ms. Wong's extensive experience combining business with science and technology will be valuable for maintaining the high quality of our nationally recognized Core Facilities as well as helping to guide the evolving needs of the research community in the future. Please join us in congratulating Ms. Wong as she assumes her new role.

### **New Funding Program Available – Proposal Preparation Funding Program**

The Office of Research announces a new funding mechanism, the "Proposal Preparation Funding Program." The goal of the program is to provide funds to support the submission of multi-investigator grants such as program projects, center proposals, U awards, etc. This program is not designed to provide support for submission of individual R01-type grants. The funds may be utilized to offset the cost of temporary secretarial, administrative and/or expert services required to assemble and submit large proposals. The program will provide funds up to \$10,000. For further details on the application process, please visit (<http://www.med.umich.edu/medschool/research/support/funding/proposalprep.htm>).

## **New NIH Website Guides Extramural Researchers During Emergencies**

The NIH has developed a new webpage for the extramural research community outlining the agency's response to national disasters and other emergencies. The site includes guidance, notices, and other information of particular relevance to investigators and their institutions, as well as links to similar emergency response resources from other federal agencies. In an emergency, the NIH's immediate response is to protect the health and safety of people and animals in the programs it oversees, and to preserve the health of the biomedical research enterprise in the area affected by the emergency. For more information, visit ([http://grants.nih.gov/grants/natural\\_disasters.htm](http://grants.nih.gov/grants/natural_disasters.htm)).

## **Updated Engage Website Makes It Easier for People to Participate in Health Research**

If you are one of those people who want medical cures and health care solutions to happen more quickly, now you can do something about it: help with the research that can find those cures and solutions. An updated Michigan Institute of Clinical and Health Research (MICHR) Engage website makes it easier than ever to help patients and other community members learn about and volunteer to participate in clinical research studies.

The Engage site was first launched in 2005, and a volunteer registry was initially released in January 2007 to give interested people a way to participate in U-M clinical research. This registry helps UMHS investigators recruit people for clinical studies. Over 2,500 volunteers have registered – an increase of nearly 2000 volunteers – since the effort to improve the website began last year.

Recently overhauled to add new features and easier searching, the Engage website consists of several important parts:

- A database of medical studies at U-M that currently need volunteers.
- Information about clinical research for the public.
- Multicultural research pages.
- Information for U-M study teams.
- A registry that allows prospective volunteers to enter their information so that they can be contacted directly by researchers who need people with their particular medical condition or health profile.

For more information, to search studies, or to join the U-M Engage registry, visit (<http://www.umengage.org>).

## **Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS)**

***(This is part of a continuing series of articles describing the services available through the Office of Research and affiliated units.)***

M-NIMBS was founded in 2005 as a multidisciplinary team of chemists, physicists, engineers, pharmacists, (bio)informatics specialists and biologists collaborating on nanoscience in biology and medicine. The interaction of these various groups accelerates discovery in nanoscience. M-NIMBS has an Executive Committee as well as an External

Advisory Board to help direct its efforts. Some of the major activities include:

### **• Research**

Research at M-NIMBS is based on several nanotechnology platforms including dendrimers, nanoemulsions and metal nanoparticles. The dendrimer-based technology includes examination of nanoparticle interactions with membranes, synthesis and characterization of novel nanoparticles for targeted cancer treatment and MRI contrast enhancement, as well as development of minimally invasive two photon fiber optic probes for detection and diagnosis of cancer. Therapeutic and/or diagnostic agents are covalently attached to this scaffolding through chemical linkers. Targeting vectors are attached to the dendrimers and serve as precision guidance systems that direct the therapeutic agents to sites of disease while bypassing healthy tissue.

To address the unique requirements for analgesia under battlefield conditions, we are developing a prodrug and/or dendrimer-based multifunctional nanodevice to engineer a controlled release analgesic that will be safe to administer under battlefield conditions without close monitoring of the injured.

Our nanoemulsion-based technology has demonstrated to possess efficient topical antimicrobial activity as well as powerful mucosal adjuvant capability. The antimicrobial activity is of a broad spectrum, affecting enveloped viruses, bacteria (mostly Gram positives), spores, and fungi. As an adjuvant, the nanoemulsion induces protection against pneumonitis in mice immunized with a mixture of nanoemulsion and influenza A virus and induces HIV-neutralizing antibody production in mice that have been immunized with a mixture of nanoemulsion and recombinant HIV gp120 protein. We have promising ongoing nasal vaccine effectiveness studies for hepatitis B virus, influenza virus, *B. anthracis* and smallpox (vaccinia virus) as well as against *Burkholderia Cenocepacia* to aid in the treatment of Cystic Fibrosis. Importantly, due to the nanoemulsion's innate pathogenicity and its stability over a wide range of temperatures, refrigeration is not required for these nanoemulsion adjuvant vaccines.

In each of these cases, the success of the investigation required the interdisciplinary skills provided by a team of researchers drawn from across campus.

### **• Events and Programs**

M-NIMBS offers The Ted Doan Nanotechnology Lecture Series several times per year and hosts a Symposium on Nanotechnology with invited speakers annually. We hold a LSA research theme semester on "nanotechnology" which includes a series of lectures on nanoscience, some for researchers and some for the general public. One objective is to stimulate discussion on the ethical implications of this rapidly advancing technology. The M-NIMBS membership gathers monthly for a luncheon meeting with member and student presentations.

### **• Education**

We offer a Certificate Program in Nanobiology through the Rackham Graduate School to provide a cross-cutting certificate program that will prepare students

from biological disciplines to undertake modern nanotechnology research as well as students from physical science disciplines to undertake modern biological research. We integrate students from a number of existing graduate programs within this interdisciplinary research structure and thereby provide a coherent strategy for educating students more broadly in nanobiology while still maintaining intellectual depth in a core discipline.

For more information, visit the M-NIMBS website at (<http://nano.med.umich.edu>).

## RESEARCH COMPLIANCE TRAINING AND EDUCATION

### *Human Research*

#### **New IRBMED Informed Assent Document Template**

On 9/13/08, the IRBMED posted an assent template recommended for children ages 10 to 14 on those studies where assent is required. The assent template is posted on the webpage with informed consent templates (<http://www.med.umich.edu/irbmed/ict.htm>). A template for children ages 7 to 9 is in the works. We also posted the "Guidelines for Use by the IRBMED in Determining When Assent of Children Should be Waived or Required." These are on the Guidance webpage under "Children in Research - Assent Guidelines" (<http://www.med.umich.edu/irbmed/guidance/Child-Assent%20Guidelines.pdf>).

The new assent template and guidance are part of a larger effort to make it easier for investigators to implement and follow the federal regulations regarding assent. Use of the assent template is a recommendation rather than a requirement. Although there will not be a requirement for existing studies to change-over to using it, investigators should be aware that the IRB may ask questions about or require changes to a study's assent process at the next amendment or at the time of renewal. We recommend investigators review the new template and the information below, and then review the information in their IRB applications and current assenting processes and documents. Consider if any adjustments are appropriate to the study prior to submitting the next amendment or renewal.

Regulations require that for each study involving children the IRB determine:

1. If some or all children are capable of providing assent.
2. If a waiver of assent is appropriate for some or all subjects.
3. When assent is required:
  - Determine adequate provisions are made for soliciting assent.
  - Assess the form and content of the information conveyed to the prospective subjects.
  - Decide if assent should be documented and, if so, how.

If an assent process is approved for a study, that means **it is required** for all children (unless exceptions to this general rule are also indicated in the application and approved by

the IRBMED). When assent is required, the **researchers must honor a child's dissent**, even if the parents want the child to be in the research.

There are three conditions under which the regulations permit assent waiver:

1. Capabilities of some or all children is so limited they **cannot** be consulted.
2. Study offers important benefit **unavailable outside of the research** (when the study offers a treatment that is thought to be a better option than those currently available, or it offers the only alternative). **Note, this is a more stringent standard than "potential of direct benefit."**
3. Assent may also be waived under the same criteria as a consent waiver:
  - The study is minimal risk.
  - Subjects' rights and welfare aren't adversely affected.
  - Assent is not practicable (for reasons **other than** children's capabilities).
  - When appropriate, the subjects will be provided pertinent information.

Please contact the office at 734-763-4768 or ([irbmed@umich.edu](mailto:irbmed@umich.edu)) if you have any questions about the assent template, regulations regarding assent, or the assent process. If you would like to schedule an educational session for your unit or department on this topic, we will be happy to provide that as well.

### *Animal Research*

#### **Notice of Revised UCUCA Policy**

The UCUCA Policy on Analgesic Use in Animals Undergoing Surgery has been revised! This policy has been revised in an effort to inform investigators of the minimum required use of analgesics in animals that undergo study-related surgical procedures at the University of Michigan. All protocols will have to be converted to comply with the policy within one year. If you are planning on submitting an amendment, please include any changes to comply with the policy at this time. If you will not be submitting an amendment in the near future, the UCUCA office will contact you within one year to update your protocol to comply with the new policy. If you have any questions about this newly revised policy, please contact the UCUCA office ([ucuca.office@umich.edu](mailto:ucuca.office@umich.edu)). If you would like assistance in reviewing your current protocol for compliance with this policy, please contact the ULAM veterinary staff ([ulamvets@umich.edu](mailto:ulamvets@umich.edu)). To access the new policy, please go (<http://www.ucuca.umich.edu/guidesurg.htm>) and click the link for the document "UCUCA Policy on Analgesic Use in Animals Undergoing Surgery."

## FREQUENTLY ASKED QUESTIONS

The frequently asked questions (FAQs) highlighted here come from a list of FAQs for research maintained by the Office of Research. To see the complete list, visit (<http://www.med.umich.edu/medschool/research/faq.htm>).

### **Q) If I only want to look at data of deceased persons, do I need IRB approval?**

**A)** No. Deceased persons are not considered human subjects by the regulatory definition. However, you still need to request approval from the Privacy Review Board by completing the request form (<http://www.med.umich.edu/irbmed/PB/PrivacyBoard.htm>).

### **Q) If I want to use data from an IRB approved database, do I need IRB approval?**

**A)** Yes, you need approval for the purpose of the extraction of data from the IRB approved database. The IRB needs to approve a data registry and then any subsequent extractions of data will need additional/separate IRB approval.

## FUNDING/AWARD OPPORTUNITIES

Abstracts listed here are meant to raise awareness about funding opportunities. We strongly urge interested applicants to visit the listed website to verify complete eligibility, program information, and application procedures before submitting an application.

To search for other funding and recognition opportunities, visit (<http://www.med.umich.edu/medschool/research/support/funding.htm>). This webpage contains a link to M-Quest (a database of opportunities for grants, honors, prizes and fellowships created and maintained by the Office of Research) as well as information on email alert groups and upcoming limited submissions.

### *Internal Submissions*

#### **UM Life Sciences Institute Center for Chemical Genomics - Collaborative Pilot Project Grants Deadline: November 3, 2008 (5:00 PM)**

The Center for Chemical Genomics (CCG) in the Life Sciences Institute (LSI), in partnership with Thermo Fisher Scientific, Inc. (TMO) announces its fourth year of funding to promote the advancement of drug discovery technologies at the University of Michigan. The focus of the Center is to facilitate the use of high throughput screening (HTS) approaches within the academic community to accelerate the discovery of molecular research tools (e.g., ligands, imaging probes, and new activities of existing drugs). The CCG provides assay development and implementation support along with HTS facilities for discovery of new bioactive agents. The CCG also provides chemoinformatics support through programming, database, and SAR.

The TMO pilot project initiative is meant to foster the discovery or development of novel technologies both within and outside the LSI relating to high throughput screening (HTS) and detection capabilities, protein expression, chemical diversity and bioinformatics. Financial support to run existing screens is not provided by this program, but use of CCG resources to advance highly innovative screening technol-

ogies may be appropriate. Pilot projects will be supported for a period of one year with the option of competing for a second year, with the intent to provide seed funds to permit investigators to gather preliminary data for external funding.

All University of Michigan faculty holding the rank of assistant professor, assistant research scientist, or above are eligible to apply for these funds. **It is highly advisable to contact the CCG leadership regarding utilization of equipment or collaboration prior to submission.** Additional information and forms can be downloaded at (<http://www.lsi.umich.edu/ccg>) or by contacting Vashni Santee at ([santee@umich.edu](mailto:santee@umich.edu)).

#### **UM Comprehensive Cancer Center Breast Cancer Research Grants Deadline: November 6, 2008**

The UM Comprehensive Cancer Center (UMCCC) is pleased to announce the availability of funds to support breast cancer research proposals. Both fundamental studies (e.g., emphasis on novel concepts and mechanisms) and translational studies (with emphasis on translation of concepts developed in the applicant's research program) will be considered.

**The Cancer Research Committee will consider applications only from University of Michigan faculty who hold appointments of the following types:**

- **Instructional Track** – Lecturer, Assistant Professor, Associate Professor, Full Professor
- **Clinical Track** – Instructor, Clinical Assistant Professor, Clinical Associate Professor, Clinical Professor
- **Research Track** – Assistant Research Professor, Associate Research Professor, Research Professor

Applications are limited to one year of support, with a budget of up to \$50,000 that can be used for personnel, supplies, small equipment purchase, or other reasonable costs (e.g., animal purchase and maintenance or core laboratory usage). Visit ([http://sitemaker.umich.edu/ccresearch/cancer\\_research\\_committee\\_crc\\_grants](http://sitemaker.umich.edu/ccresearch/cancer_research_committee_crc_grants)) to access the RFA. If you have any questions, please contact Dr. Eric Fearon (734-764-1549 or [efearon@umich.edu](mailto:efearon@umich.edu)) or Mary Rexer (734-936-9603 or [maryrex@umich.edu](mailto:maryrex@umich.edu)).

#### **UM Institute for Research on Women and Gender - Gender and Global Health Faculty Seed Grants Deadline: November 12, 2008 (4:00 PM)**

The UM Institute for Research on Women and Gender's Gender and Global Health Program (GGH) provides seed funding of \$2,000-\$5,000 to facilitate innovative, collaborative, and high-quality research in the field of gender and global health. Criteria for funding will include importance and relevance of the proposed research to advancing global health, having an interdisciplinary research team involving multiple schools or disciplines, inclusion of foreign scholars from one or more collaborating institutions, and likelihood the project will lead to a successful grant proposal. They are specifically interested in applications that address the role of research universities in (1) attaining the Millennium Development Goals (<http://www.un.org/millenniumgoals/>), (2) meeting the challenges posed by the Global Health Forum (<http://www.globalforumhealth>).

org/Site/000\_\_Home.php), (3) facilitating multi-sectorial engagement in priority global health research, and (4) integrating a gender focus. Continuing instructional faculty, research faculty, and research scientists with a minimum 50% effort are eligible to apply. Visit (<http://ghrt.psc.isr.umich.edu/research/funding.html>) for complete details.

### **Distinguished University Innovator Award**

**Deadline: November 14, 2008**

The Office of the Vice President for Research (OVPR) is accepting nominations for the Distinguished University Innovator Award, established in 2006 to recognize individuals at the University of Michigan who have distinguished themselves through innovation as defined in the selection criteria below.

**Selection Criteria:** The Distinguished University Innovator(s) will have accomplished one or more of the following:

- Developed a breakthrough technology and demonstrated its transformational potential relative to an otherwise conventionally accepted practice or market.
- Taken a significant innovation developed in the University through to market-readiness, either through partnership with a commercial enterprise, or by starting a company.
- Demonstrated a new method or means for moving innovations from the university into the private sector through the establishment of partnerships or other relationships that promote the strategic or economic position of the region, state or nation.

A member of the tenure/tenure track or research faculty, or a team of up to three individuals led by such faculty member are eligible for nomination. An honorarium of \$5,000 will be given to the individual winner or shared by the team winners. The awardee will be announced in January 2009, and the recipient will be invited to deliver a lecture in the spring of 2009. Nomination guidelines are available at ([http://www.research.umich.edu/contacts/ovpr/innovator\\_award](http://www.research.umich.edu/contacts/ovpr/innovator_award)). If you have any questions, please contact the Office of the Vice President for Research at 734-763-1290.

### **UM Initiative on Rare Disease Research Grant Program**

**Deadline: December 19, 2008 (5:00 PM)**

Orphan diseases are defined as those with a prevalence of less than 200,000 patients in the United States. The study and treatment of orphan diseases are the focus of a considerable fraction of the basic science, clinical research, and clinical care conducted at the University of Michigan. Funds have been made available by the Office of the Vice President for Research, Medical School Dean's Office, and Department of Internal Medicine to provide seed funding for multidisciplinary efforts in rare disease research.

The goals of this program include the promotion of synergistic interactions of investigators across the University, the support of high-risk preliminary studies that may lead to external grant support, the identification of core strengths in rare disease research at the University, and the development of a better understanding of research questions and problems that are specific to the study of limited populations. The

response to this request for proposals will be one measure by which the feasibility, justification, and need for a sustained program on rare diseases will be assessed.

This is a one-time grant program with funds to be allocated for a period of one year. While cost sharing by the applicant's department or center is not a prerequisite, preference will be given to proposals that are supplemented by the applicant's department. This program offers the following two types of grants:

- **Pilot Grants** – Up to \$30,000 will be made available for investigator-initiated, hypothesis driven grants that focus on rare disease research. Up to \$100,000 will be made available for the establishment of collaborative multidisciplinary programs focused on disease mechanisms. The funds will be available for a 12-month period from the start of the grant; unused funds will be returned.
- **Symposia Grants** – Up to \$20,000 will be made available to support research symposia in the general area of orphan diseases.

For complete information, visit ([http://www.research.umich.edu/funding/um\\_sources/rarediseases.html](http://www.research.umich.edu/funding/um_sources/rarediseases.html)) or contact Karen Banks at ([karbanks@umich.edu](mailto:karbanks@umich.edu)).

### *External Limited Submissions*

#### **Camille Dreyfus Teacher-Scholar Awards Program**

**Internal Deadline: December 5, 2008**

**Foundation Deadline: February 5, 2009**

The Camille Dreyfus Teacher-Scholar Awards Program supports the research and teaching careers of talented young faculty in the chemical sciences. Criteria for selection include an independent body of scholarship attained within the first five years of appointment as an independent researcher and a demonstrated commitment to education, signaling the promise of continuing outstanding contributions to both research and teaching. Nominations must provide compelling evidence of the advance of important knowledge in the chemical sciences by the nominee. Further, the nomination should describe dedication and contributions to education in the chemical sciences, particularly with respect to undergraduates.

**Nominees must hold a full-time tenure-track academic appointment and are normally expected to be within the first five years of their independent academic careers, with appointment date no earlier than mid-year 2003. The University of Michigan is allowed to nominate only one faculty member for this award.** For consideration as the institutional nominee, submit the following **electronically in a single PDF document by December 5, 2008 to ([OVPRlimitedsubmissions@umich.edu](mailto:OVPRlimitedsubmissions@umich.edu)):**

- NIH formatted biosketch, including a list of relevant publications.
- Letter of nomination from an institutional representative (typically the department chair) highlighting the nominee's achievements, and the basis for selection.
- A description (no more than 2 pages) of the nominee's research plans as well as a statement on teaching.
- A budget (less than 1 page) describing how award funds will be used.

- The **names only** of three people outside of the UM personally familiar with the candidate's work and creative ability. At least one of the names must be from a person who has had no supervisory or collaborative contact with the candidate.

Visit ([http://www.dreyfus.org/awards/camille\\_dreyfus\\_teacher\\_award.shtml](http://www.dreyfus.org/awards/camille_dreyfus_teacher_award.shtml)) for more information. Contact Jane Ritter ([ritterj@umich.edu](mailto:ritterj@umich.edu) or 734-763-1290) with any questions.

### *External Open Submissions*

#### **Bill & Melinda Gates Foundation Grand Challenges Explorations Grants Deadline: November 2, 2008**

The Bill & Melinda Gates Foundation seeks novel ideas from every scientific discipline as part of its new grantmaking initiative. Grand Challenges Explorations will foster innovation in global health research and expand the pipeline of ideas that merit further exploration. The initiative will use an agile, accelerated grant-making process with short two-page applications and no preliminary data required. Initial grants will be awarded multiple times per year at approximately \$100,000 each. Additional funding of \$1 million or more will be available for projects that show promise. Applications for Grand Challenges Explorations Round 2 are now being accepted, and the topics are:

- Create New Vaccines for Diarrhea, HIV, Malaria, Pneumonia, and Tuberculosis
- Create New Tools to Accelerate the Eradication of Malaria
- Explore the Basis for Latency In Tuberculosis
- Create New Ways to Prevent or Cure HIV Infection
- Create New Ways to Protect Against Infectious Disease
- Create New Drugs and Delivery Systems To Limit the Emergence of Resistance

For more information and complete application details, visit (<http://www.gcgh.org/explorations>). The Grand Challenges Explorations grant program is a part of the Grand Challenges in Global Health initiative, which aims to engage creative minds from across scientific disciplines—including those who have not traditionally taken part in global health research—to work on 14 major challenges.

#### **American Cancer Society Funding Deadline: December 1, 2008**

The American Cancer Society offers the following funding opportunities. Visit ([http://www.cancer.org/docroot/RES/RES\\_5\\_1.asp?sitearea=RES](http://www.cancer.org/docroot/RES/RES_5_1.asp?sitearea=RES)) for complete details.

- **International Fellowships for Beginning Investigators**  
The fellowships are funded by the American Cancer Society with the objective of fostering a bi-directional flow of knowledge, experience, expertise, and innovation between countries. These 12 month long fellowships are intended for beginning investigators and clinicians who are in the early stages of their careers. Funding preference will be given to candidates who propose to conduct cancer research projects into the preclinical, clinical, epidemiology, psychosocial, behavioral, health services, health policy and outcomes and cancer control.

Eligible candidates should hold assistant professorships or similar positions at their home institutes and have at least two years of postdoctoral experience after obtaining their M.D. or Ph.D. degrees or equivalents. Awards are conditional on the return of the Fellow to the home institute at the end of the fellowship and on the availability of appropriate facilities and resources to apply the newly acquired skills. No extensions are permitted. Between 6-8 Fellows are selected each year for awards with an average value of \$45,000 for travel and stipend support.

- **Audrey Meyer Mars International Fellowships in Clinical Oncology**

These fellowships provide one year of advanced training in clinical oncology at participating U.S. cancer centers to qualified physicians and dentists from other countries, particularly countries where advanced training is not readily available. This program provides up to \$45,000 annual funding.

#### **Dreyfus Prize in the Chemical Sciences Deadline: February 13, 2009**

The Camille and Henry Dreyfus Foundation announces the establishment of the Dreyfus Prize in the Chemical Sciences. The prize will be awarded to an individual in a selected area of chemistry to recognize exceptional and original research that has advanced the field in a major way. The first Dreyfus Prize will be awarded in the field of materials chemistry. (Note that due to the nature of the selected topic, candidates may reside outside the chemistry department.) The prize, to be awarded biennially, will consist of a citation, a medal, and a monetary award of \$250,000.

Any person may nominate a candidate for the Dreyfus Prize in the Chemical Sciences. **Self-nominations are not accepted. The prize is restricted to U.S. residents.** Nobel laureates are not eligible. For complete information and application procedure, visit (<http://www.dreyfus.org/awards/prize.shtml>).

### *• • • Deadline Watch • • •*

#### **Clinical Research Masters Program - Call for Applications**

**Deadline: October 17, 2008**  
(<http://www.michr.umich.edu/K30>)

#### **UM Center for Computational Medicine and Biology (CCMB)**

**Pilot Research Grant Program**  
**Deadline: October 20, 2008**  
(<http://www.med.umich.edu/medschool/research/support/funding/ccmbpilot.htm>)

#### **Edward M. Scolnick Prize in Neuroscience**

**Deadline: October 31, 2008**  
([http://web.mit.edu/mcgovern/html/News\\_and\\_Publications/scolnick\\_prize.shtml](http://web.mit.edu/mcgovern/html/News_and_Publications/scolnick_prize.shtml))

#### **Canada Gairdner Global Health Award**

**Deadline: November 1, 2008**  
(<http://www.gairdner.org/awards>)

#### **Charlotte Geyer Foundation Grants**

**Deadline: November 15, 2008**  
(<http://www.charlottegeyer.org>)

#### **Warren Alpert Foundation Prize**

**Deadline: November 17, 2008**  
(<http://www.hms.harvard.edu/fa/alpertprize>)

# UMMS AWARDED GRANTS

## External Awarded Grants

### Anesthesiology

**PI:** Opp, Mark  
**Co-I:** Imeri, Luca (Anesthesiology Department)  
**Title:** CYTOKINE AND NEUROTRANSMITTER INTERACTIONS IN SLEEP REGULATION  
**Sponsor:** NIH 2 R56 MH 064843 06 A1  
**Project Dates and Amount of Award:** 09/01/08-08/31/09; \$372,200

### Comprehensive Cancer Center

**PI:** Wolf, Gregory  
**Co-I:** Bradford, Carol (Kresge Hearing Research Inst) / Bump, Gregory (School of Nursing) / Carey, Thomas (Kresge Hearing Research Inst) / Chepeha, Douglas (Otorhinolaryngology Department) / Cordell, Kitrina (Oral Med / Path / Oncology) / D'Silva, Nisha (Oral Med / Path / Oncology) / Eisbruch, Avraham (Radiation Oncology - Ann Arbor) / Gruber, Stephen (Int Med-Molecular Med&Genetics) / Lawrence, Theodore (Radiation Oncology - Ann Arbor) / Longworth, Zora (Department of Family Medicine) / Lubman, David (Surgery Department) / Mchugh, Jonathan (UMH H.O. Core Pathology) / Nor, Jacques (Cariology, Restor Sci & Endo) / Normolle, Daniel (Radiation Oncology - Ann Arbor) / Nyati, Mukesh (Radiation Oncology - Ann Arbor) / Polverini, Peter (School of Dentistry) / Taylor, Jeremy (Biostatistics Department) / Teknos, Theodoros (Otorhinolaryngology Department) / Wang, Shaomeng (Int Med-Hematology / Oncology) / Worden, Francis (Int Med-Hematology / Oncology)  
**Title:** SPORE IN HEAD AND NECK CANCER: THE MOLECULAR BASIS OF HEAD AND NECK CANCER BIOLOGY, TREATMENT AND PREVENTION  
**Sponsor:** NIH 2 P50 CA 097248 06 A1  
**Project Dates and Amount of Award:** 09/02/08-06/30/13; \$13,975,000

### Dermatology

**PI:** Bruce, Allen  
**Title:** PHENOTYPE AND FUNCTION OF IL-17-SECRETING T-CELLS IN PSORIASIS  
**Sponsor:** National Psoriasis Foundation  
**Project Dates and Amount of Award:** 03/01/08-02/28/09; \$50,000

### Human Genetics

**PI:** Antonellis, Anthony  
**Title:** GENETIC AND GENOMIC APPROACHES FOR STUDYING INHERITED PERIPHERAL NEUROPATHIES  
**Sponsor:** NIH 4 R00 NS 060983 02  
**Project Dates and Amount of Award:** 09/16/08-08/31/11; \$739,853

### Internal Medicine

**PI:** Anumonwo, Justus  
**Co-I:** Delmar, Mario (Int Med-Cardiology) / Vikstrom, Karen (Int Med-Cardiology)  
**Title:** MOLECULAR DETERMINANTS OF FUNCTION IN KIR2.X CHANNELS  
**Sponsor:** NIH 7 R01 GM 076608 02  
**Project Dates and Amount of Award:** 04/01/08-08/31/12; \$1,380,735

**PI:** Aronoff, David  
**Co-I:** Harris, Lisa (Obstetrics and Gynecology Dept) / Peters-Golden, Marc (Int Med-Pulm. / Critical Care) / Young, Vincent (Int Med-Infectious Diseases)  
**Title:** ROLE OF MISOPROSTOL IN CLOSTRIDIUM SOREDELLII ENDOMETRITIS AFTER MEDICAL ABORTION  
**Sponsor:** NIH 1 R01 HD 057176 01 A1  
**Project Dates and Amount of Award:** 09/01/08-05/31/13; \$1,636,901

**PI:** Baker, Laurence  
**Co-I:** Hoban, Carolyn (Int Med-Hematology / Oncology) / Schott, Anne (Int Med-Hematology / Oncology)  
**Title:** SWOG CCOP RESEARCH BASE, PCPT / PCPT LTFU, AND SELECT PROGRAMS  
**Sponsor:** NIH 7 U10 CA 037429 24  
**Project Dates and Amount of Award:** 06/01/08-05/31/12; \$66,854,439

**PI:** Baptist, Alan  
**Title:** EXHALED NITRIC OXIDE AND ASTHMA EXACERBATIONS IN AFRICAN AMERICAN CHILDREN  
**Sponsor:** American Academy of Allergy, Asthma and Immunology (AAAAI)  
**Project Dates and Amount of Award:** 11/01/08-10/31/09; \$50,000

**PI:** Blaum, Caroline  
**Co-I:** Bernstein, Steven (Int Med-General Medicine) / Choe, Hae Mi (College of Pharmacy) / Rogers, Mary (Int Med-General Medicine)

**Title:** OUTCOMES OF BLOOD PRESSURE MANAGEMENT IN DIABETES PATIENTS WITH COMORBIDITIES  
**Sponsor:** AHRQ 1 R21 HS 017625 01  
**Project Dates and Amount of Award:** 09/30/08-09/29/10; \$312,158

**PI:** Brenner, John  
**Title:** DISSECTING THE MOLECULAR MECHANISM OF RHOC GTPASE EXPRESSION IN THE NORMAL AND MALIGNANT BREAST  
**Sponsor:** US DOD-Army, Department of the  
**Project Dates and Amount of Award:** 09/01/08-09/30/11; \$94,427

**PI:** Brook, Robert  
**Title:** NOVEL EXPOSURE SCENARIOS TO DEFINE THE HEALTH EFFECTS OF PARTICLE SOURCES  
**Sponsor:** Environmental Protection Agency-Subcontracts TO St. Michael's Hospital  
**Project Dates and Amount of Award:** 10/01/06-09/30/10; \$54,946

**PI:** Chen, Grace  
**Title:** ROLE OF THE IMMUNE RECEPTOR NOD1 IN INFLAMMATION-ASSOCIATED COLON TUMORIGENESIS  
**Sponsor:** NIH 1 K08 CA 133185 01 A1  
**Project Dates and Amount of Award:** 09/16/08-08/31/12; \$532,480

**PI:** Chugh, Aman  
**Co-I:** Bogun, Frank (Int Med-Cardiology) / Good, Eric (Int Med-Cardiology) / Jongnarangsin, Krit (Int Med-Cardiology) / Oral, Hakan (Int Med-Cardiology) / Pelosi Jr, Frank (Int Med-Cardiology)  
**Title:** FREEDOM: A FREQUENT OPTIMIZATION STUDY USING THE QUICKOPT METHOD  
**Sponsor:** St. Jude Medical, Inc.  
**Project Dates and Amount of Award:** 02/11/08-02/10/11; \$41,403

**PI:** Clauw, Daniel  
**Co-I:** As-Sanie, Sawsan (Obstetrics and Gynecology Dept) / Clemens, James (Int Med-Rheumatology) / Gracely, Richard (Int Med-Rheumatology) / Harris, Richard (Int Med-Rheumatology) / Oldendorf, Ann (Urology Surgery) / Williams, David (Int Med-Rheumatology)  
**Title:** UNIVERSITY OF MICHIGAN MAPP RESEARCH NETWORK DISCOVERY SITE  
**Sponsor:** NIH 1 U01 DK 082345 01  
**Project Dates and Amount of Award:** 09/15/08-06/30/13; \$4,772,276

**PI:** Elmunzer, Badih  
**Title:** ENDOSCOPIC FULL THICKNESS RESECTION OF GASTRIC LESIONS USING A NOVEL GRASP-AND-SNARE TECHNIQUE EVALUATION IN A PORCINE SURVIVAL MODEL  
**Sponsor:** Natural Orifice Surgery Consortium for Assessment and Research (NOSCAR)  
**Project Dates and Amount of Award:** 09/01/08-08/31/09; \$26,500

**PI:** Garg, Puneet  
**Title:** ROLE OF COFILIN IN PODOCYTE ACTIN CYTOSKELETON DYNAMICS  
**Sponsor:** National Kidney Foundation  
**Project Dates and Amount of Award:** 07/01/08-06/30/10; \$100,000

**PI:** Gruber, Stephen  
**Co-I:** Turgeon, Danielle (Int Med-Gastroenterology)  
**Title:** UMCC 2008.007: CELECOXIB IN GENOTYPE POSITIVE SUBJECTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (A PHASE III PLACEBO-CONTROLLED TRIAL OF)  
**Sponsor:** Pfizer Incorporated TO INC Research, Inc  
**Project Dates and Amount of Award:** 07/03/08-07/02/16; \$903,760

**PI:** Huang, Steven  
**Title:** EPIGENETIC REGULATION OF THE E PROSTANOID 2 GENE IN LUNG FIBROBLASTS  
**Sponsor:** American Thoracic Society (ATS)  
**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$50,000

**PI:** Hussain, Maha  
**Title:** UMCC 2008.013--IMC-A12 OR IMC-1121B PLUS MITOXANTRONE AND PREDNISON IN METASTATIC ANDROGEN-INDEPENDENT PROSTATE CANCER (AIPC) FOLLOWING DISEASE PROGRESSION ON DOCETAXEL-BASED CHEMOTHERAPY (A PHASE 2, MULTICENTER, RANDOMIZED STUDY OF)  
**Sponsor:** ImClone Systems Inc. TO ICON Clinical Research, Inc.  
**Project Dates and Amount of Award:** 09/01/08-08/31/11; \$831,002

**PI:** Jalife, Jose  
**Title:** SPECTRAL PROPERTIES OF WAVE PROPAGATION FREQUENCY AND FRACTIONATION IN ACUTE VERSUS CHRONIC ATRIAL FIBRILLATION  
**Sponsor:** National Cardiovascular Research Centre Foundation (CNIC) TO Foundation for Biomedical Research of Gregorio Maranon Hospital  
**Project Dates and Amount of Award:** 01/09/08-01/01/12; \$190,117

**PI:** Kaul, Daniel  
**Co-I:** Riddell IV, James (Int Med-Infectious Diseases) / Smith, Jeannina (Int Med-Infectious Diseases)  
**Title:** CELL MEDIATED IMMUNITY AND THE PREDICTION OF CYTOMEGALOVIRUS DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS  
**Sponsor:** University of Alberta Foundation TO University of Alberta  
**Project Dates and Amount of Award:** 08/27/08-08/26/11; \$3,333

**PI:** Krein, Sarah  
**Co-I:** Banaszak-Holl, Jane (Health Management and Policy) / Hofer, Timothy (Int Med-General Medicine) / Saint, Sanjay (Int Med-General Medicine)  
**Title:** IMPLEMENTING EVIDENCE TO PREVENT URINARY INFECTION AND ENHANCE PATIENT SAFETY  
**Sponsor:** NIH 1 R01 NR 010700 01  
**Project Dates and Amount of Award:** 08/25/08-04/30/12; \$1,714,114

**PI:** Langa, Kenneth  
**Title:** CHANGES IN COGNITIVE PERFORMANCE IN PRECLINICAL AD: A COLLABORATIVE ANALYSIS  
**Sponsor:** NIH - Subcontracts TO University of South Florida  
**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$37,500

**PI:** Li, Ying  
**Title:** CHARACTERIZE DOSE-DEPENDENCE EFFECTS AND TIME COURSE OF THREE ANTAGONISTS ON CISPLATIN-INDUCED INCREASES IN VAGAL AFFERENT SPONTANEOUS ACTIVITY AND THE ENHANCED NEURONAL RESPONSES TO SP  
**Sponsor:** MGI Pharma Inc  
**Project Dates and Amount of Award:** 09/04/08-07/31/09; \$150,005

**PI:** McCune, William  
**Co-I:** Somers, Emily (Int Med-Rheumatology)  
**Title:** MICHIGAN LUPUS REGISTRY  
**Sponsor:** CDC-Subcontracts TO National Association for Chronic Disease Directors  
**Project Dates and Amount of Award:** 04/01/08-06/30/09; \$93,750

**PI:** McCune, William  
**Co-I:** Cagnoli, Patricia (Int Med-Rheumatology) / Marder, Wendy (Int Med-Rheumatology)  
**Title:** CTLA4LG (ABATACEPT) PLUS CYCLOPHOSPHAMIDE VS CYCLOPHOSPHOMIDE ALONE IN THE TREATMENT OF LUPUS NEPHRITIS (A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE II MULTICENTER TRIAL OF)  
**Sponsor:** NIH - Subcontracts TO University of California - San Francisco  
**Project Dates and Amount of Award:** 01/01/08-10/31/08; \$18,880

**PI:** McLaughlin, Vallerie  
**Co-I:** Chan, Kevin (Int Med-Pulm./Critical Care) / Martinez, Fernando (Int Med-Pulm./Critical Care) / Rubenfire, Melvyn (Int Med-Cardiology)  
**Title:** A SINGLE-DOSE, DOSE-ESCALATING STUDY EXPLORING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF INHALED TREPROSTINIL SODIUM USING THE NEBU-TEC OPTINEB INHALATION DEVICE IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH IDIOPATHIC PULMONARY FIBROSIS  
**Sponsor:** Lung Rx, Inc.  
**Project Dates and Amount of Award:** 08/12/08-08/31/09; \$90,226

**PI:** Munoz, Viviana  
**Title:** ELECTROTONIC COUPLING BETWEEN MYOFIBROBLASTS AND MYOCYTES MODULATES THE DYNAMICS OF WAVE PROPAGATION  
**Sponsor:** Heart Rhythm Society  
**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$50,000

**PI:** Pelosi Jr, Frank  
**Title:** BOSTON SCIENTIFIC FOUNDATION FELLOWSHIP  
**Sponsor:** Boston Scientific Foundation  
**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$65,000

**PI:** Phillips, Kristine  
**Title:** PATHOPHYSIOLOGY OF SYSTEMIC SCLEROSIS  
**Sponsor:** Amer College of Rheumatology  
**Project Dates and Amount of Award:** 07/01/08-06/30/10; \$100,000

**PI:** Pop-Busui, Rodica  
**Co-I:** Feldman, Eva (Neurology Department) / Srinivasan, Ashok (Radiology Department)  
**Title:** DIFFUSION TENSOR IMAGING OF SURAL NERVES IN DIABETIC PERIPHERAL NEUROPATHY  
**Sponsor:** Juvenile Diabetes Research Foundation International (JDRF)  
**Project Dates and Amount of Award:** 09/01/08-08/31/11; \$604,142

**PI:** Reisman, David  
**Title:** BRM PROMOTER POLYMORPHISM, A MARKER FOR CANCER RISKS  
**Sponsor:** NIH 1 R03 CA 128038 01 A1  
**Project Dates and Amount of Award:** 09/15/08-08/31/10; \$154,500

**PI:** Riddell IV, James  
**Title:** MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS (AN INTERNATIONAL, MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF)  
**Sponsor:** Pfizer Incorporated TO ICON Clinical Research, Inc.  
**Project Dates and Amount of Award:** 09/04/08-08/31/16; \$87,212

**PI:** Rosenthal, Devin  
**Title:** INTERACTIONS BETWEEN INFLAMMATORY BREAST CANCER AND ITS TISSUE MICROENVIRONMENT: THE MAKING OF AND INVADING INTO THE VASCULATURE  
**Sponsor:** US DOD-Army, Department of the  
**Project Dates and Amount of Award:** 09/01/08-09/30/11; \$97,068

**PI:** Scheiman, James  
**Co-I:** Finks, Jonathan (General Surgery Section)  
**Title:** NEOPLASIA DETECTION IN PANCREATIC MASS LESIONS USING TISSUE OPTICAL SPECTROSCOPY  
**Sponsor:** National Pancreas Foundation  
**Project Dates and Amount of Award:** 09/01/08-08/31/09; \$50,000

**PI:** Wiggins, Roger  
**Co-I:** Bottoms, Stephen (Pediatrics) / Brosius III, Frank (Int Med-Nephrology) / Gadegebku, Crystal (Int Med-Nephrology) / Hildebrandt, Friedhelm (Pediatrics) / Holzman, Lawrence (Int Med-Nephrology) / Inoki, Ken (Life Sciences Institute) / Johnson, Kent (Pathology Department) / Killen, Paul (Pathology Department) / Kirschner, Beth (School of Information) / Kretzler, Matthias (Int Med-Nephrology) / Mirel, Barbara (School of Education) / Norman, Joseph (Int Med-General Medicine) / Ojo, Akinlolu (Int Med-Nephrology) / Pennathur, Subramaniam (Int Med-Nephrology) / Qin, Zhaohui (Biostatistics Department) / Woolf, Peter (Biomedical Engineering)  
**Title:** THE UNIVERSITY OF MICHIGAN GEORGE M. O'BRIEN RENAL CORE CENTER  
**Sponsor:** NIH 1 P30 DK 081943 01  
**Project Dates and Amount of Award:** 09/01/08-07/31/13; \$3,793,011

**PI:** Worden, Francis  
**Title:** BIBW 2992 VERSUS CETUXIMAB (ERBITUX) IN PATIENTS WITH METASTATIC OR RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) AFTER FAILURE OF PLATINUM-CONTAINING THERAPY WITH A CROSS OVER PERIOD FOR PROGRESSING PATIENTS (UMCC 2007.129 A RANDOMIZED OPEN-LABEL PHASE II STUDY OF)  
**Sponsor:** Boehringer Ingelheim, Ltd.  
**Project Dates and Amount of Award:** 09/03/08-09/02/10; \$180,888

**PI:** Zikmund-Fisher, Brian  
**Co-I:** Fagerlin, Angela (Behavioral & Decision Sciences) / Ubel, Peter (Behavioral & Decision Sciences)  
**Title:** LEARNING BY DOING: IMPROVING RISK COMMUNICATION THROUGH ACTIVE PROCESSING OF INTERACTIVE PICTOGRAPHS  
**Sponsor:** Foundation for Informed Medical Decision Making  
**Project Dates and Amount of Award:** 10/01/08-09/30/09; \$100,000

#### Medical Education

---

**PI:** Markel, Dorene  
**Co-I:** Blumenthal, Jane (University Library)  
**Title:** ENGAGING THE COMMUNITY IN CLINICAL RESEARCH  
**Sponsor:** NIH 1 R03 NS 065491 01  
**Project Dates and Amount of Award:** 09/30/08-08/31/10; \$77,249

#### Molecular & Behavioral Neuroscience Institute

---

**PI:** Watson, Stanley  
**Co-I:** Akil, Huda (Molecular & Behav Neurosc Inst) / Thompson, Robert (Psychiatry Department)  
**Title:** COCAINE REGULATION OF MIRNAS IN RATS WITH DIFFERING VULNERABILITY TO DRUG ABUSE  
**Sponsor:** NIH 1 R01 DA 025973 01  
**Project Dates and Amount of Award:** 09/15/08-06/30/13; \$2,021,984

**PI:** Zubieta, Jon  
**Co-I:** Hernandez, Luis (Magnetic Resonance Imaging Fac) / Peltier, Scott (Magnetic Resonance Imaging Fac)  
**Title:** DEVELOPMENT AND USE OF RTFMRI FOR SELF-CONTROL OF NICOTINE CRAVING  
**Sponsor:** NIH 1 R21 DA 026077 01  
**Project Dates and Amount of Award:** 09/15/08-06/30/10; \$564,693

#### Neurology

---

**PI:** Albin, Roger  
**Co-I:** Miller, Richard (Pathology Department)  
**Title:** NEURODEGENERATION IN AGING RETARDED MICE  
**Sponsor:** NIH 1 R21 NS 059537 01 A2  
**Project Dates and Amount of Award:** 09/01/08-07/31/10; \$292,167



**PI:** Feldman, Eva  
**Co-I:** Sullivan, Kelli (Neurology Department)  
**Title:** AN INFORMATICS APPROACH TO HUMAN SURAL NERVE BIOMARKERS OF DIABETIC NEUROPATHY  
**Sponsor:** American Diabetes Assoc, Inc.  
**Project Dates and Amount of Award:** 07/01/08-06/30/11; \$300,000

**PI:** Fink, David  
**Co-I:** Urba, Susan (Int Med-Hematology/Oncology) / Worden, Francis (Int Med-Hematology/Oncology)  
**Title:** GENE TRANSFER FOR INTRACTABLE PAIN: A PHASE I CLINICAL TRIAL TO DETERMINE THE MAXIMUM TOLERABLE DOSE OF A REPLICATION-DEFECTIVE HERPES SIMPLEX VIRUS TYPE I (HSV-1) VECTOR EXPRESSING HUMAN PREPROENKEPHALIN (NP2) IN PATIENTS WITH MALIGNANCIES  
**Sponsor:** Diamyd, Inc.  
**Project Dates and Amount of Award:** 08/19/08-07/31/13; \$568,895

**PI:** Todd, Peter  
**Title:** DEFINING THE MECHANISM OF MRNA-MEDIATED NEURODEGENERATION IN FRAGILE X TREMOR ATAXIA SYNDROME  
**Sponsor:** American Academy of Neurology  
**Project Dates and Amount of Award:** 07/01/08-06/30/10; \$130,000

**PI:** Vincent, Andrea  
**Title:** DYSLIPIDEMIA AND DIABETIC NEUROPATHY  
**Sponsor:** Juvenile Diabetes Research Foundation International (JDRF)  
**Project Dates and Amount of Award:** 09/01/08-08/31/09; \$109,464

### Neurosurgery

**PI:** Thompson Jr, Gregory B  
**Title:** RANDOMIZED EVALUATION OF CARTOID OCCLUSION AND NEURORECOGNITION (RECON)  
**Sponsor:** NIH - Subcontracts TO Columbia University  
**Project Dates and Amount of Award:** 12/01/07-11/30/08; \$13,595

### Obstetrics & Gynecology

**PI:** Dalton, Vanessa  
**Co-I:** Johnson, Timothy (Obstetrics and Gynecology Dept) / Xu, Xiao (Obstetrics and Gynecology Dept)  
**Title:** FELLOWSHIP PROGRAM IN INTERNATIONAL FAMILY PLANNING  
**Sponsor:** Buffett Foundation  
**Project Dates and Amount of Award:** 08/01/08-09/30/10; \$1,098,902

### Pathology

**PI:** Elenitoba-Johnson, Kojo  
**Title:** SJOGREN'S SYNDROME ASSOCIATED SALIVARY B-CELL LYMPHOMAGENESIS  
**Sponsor:** NIH - Subcontracts TO University of Utah R21 DE 017136  
**Project Dates and Amount of Award:** 08/01/08-07/31/09; \$29,105

**PI:** Kunkel, Steven  
**Title:** RESEARCH TRAINING IN EXPERIMENTAL IMMUNOLOGY  
**Sponsor:** NIH 2 T32 AI 007413 16  
**Project Dates and Amount of Award:** 09/01/08-08/31/13; \$2,347,190

**PI:** Maher, Christopher  
**Title:** THE ROLE OF MICRORNAs IN PROSTATE CANCER PROGRESSION  
**Sponsor:** Amer Assoc for Cancer Research  
**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$40,000

**PI:** Miller, Richard  
**Title:** LABORATORY FOR ANTI-GERIC TESTING, EVALUATION AND RESEARCH  
**Sponsor:** NIH 3 U01 AG 022303 05 S2  
**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$585,651

**PI:** Yu, Jindan  
**Title:** THE ROLE OF BETA-ADRENERGIC SIGNALING IN PROSTATE CANCER  
**Sponsor:** NIH 1 K99 CA 129565 01 A1  
**Project Dates and Amount of Award:** 09/01/08-08/31/10; \$257,184

**PI:** Zochowska, Anuska  
**Co-I:** Keep, Richard (Neurosurgery)  
**Title:** EFFECT OF NICOTINE ON POSTISCHEMIC BRAIN INFLAMMATION  
**Sponsor:** NIH 1 R21 NS 062299 01 A2  
**Project Dates and Amount of Award:** 09/20/08-06/30/10; \$370,093

### Pediatrics & Communicable Diseases

**PI:** Davis, Matthew  
**Co-I:** Freed, Gary (Pediatrics-Ambulatory Care Pgm) / Wheeler, John (Health Management and Policy)  
**Title:** UNDERSTANDING & ESTIMATING COSTS OF VACCINE DEVELOPMENT, PRODUCTION AND PRICING  
**Sponsor:** CDC 3 U01 IP 000104 02 S1  
**Project Dates and Amount of Award:** 09/15/08-09/14/09; \$41,874

**PI:** Dawid, Suzanne  
**Title:** MECHANISMS OF INTRASPECIES COMPETITION IN S. PNEUMONIAE  
**Sponsor:** MedImmune, Inc. TO Pediatric Infectious Diseases Society  
**Project Dates and Amount of Award:** 07/30/08-12/31/08; \$50,000

**PI:** Filbrun, Amy  
**Title:** PULMOZYME IN 3-5 YEAR OLD PATIENTS WITH CYSTIC FIBROSIS (PULMOZYME: Z4240G, A PHASE IV, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF)  
**Sponsor:** Genentech, Inc.  
**Project Dates and Amount of Award:** 02/01/08-09/30/09; \$50,210

**PI:** Keegan, Catherine  
**Title:** MOLECULAR AND GENETIC MECHANISMS OF CAUDAL DYSGENESIS IN ADRENOCORTICAL DYSPLASIA (ACD) MICE  
**Sponsor:** March of Dimes Birth Defect Foundation  
**Project Dates and Amount of Award:** 06/01/08-05/31/11; \$280,473

**PI:** McAllister-Lucas, Linda  
**Co-I:** Gestwicki, Jason (Pathology Department) / Lucas, Peter (Pathology Department)  
**Title:** MULTIPLE ROLES OF THE API2 MOIETY IN API2-MALT1-MEDIATED LYMPHOMAGENESIS  
**Sponsor:** NIH 1 R01 CA 124540 01 A1  
**Project Dates and Amount of Award:** 09/01/08-07/31/13; \$1,595,733

**PI:** Nasr, Samya  
**Co-I:** Arteta, Manuel (Pediatrics-Pulmonary Medicine) / Filbrun, Amy (Pediatrics-Pulmonary Medicine) / Hassan, Fauziya (Pediatrics-Pulmonary Medicine) / Hershenson, Marc (Pediatrics-Pulmonary Medicine) / Lewis, Toby (Pediatrics-Pulmonary Medicine) / Lumeng, Carey (Pediatrics-Pulmonary Medicine) / Tsai, Wan (Pediatrics-Pulmonary Medicine)  
**Title:** INHALED CIPROFLOXACIN COMPARED TO PLACEBO IN SUBJECTS WITH CYSTIC FIBROSIS (RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF)  
**Sponsor:** Bayer Corporation  
**Project Dates and Amount of Award:** 05/27/08-05/26/10; \$86,230

**PI:** Nasr, Samya  
**Co-I:** Simon, Richard (Int Med-Pulm./Critical Care)  
**Title:** CYSTIC FIBROSIS CENTER GRANT 2008-2009  
**Sponsor:** Cystic Fibrosis Foundation  
**Project Dates and Amount of Award:** 07/01/08-06/30/09; \$188,270

**PI:** Russell, Mark  
**Title:** PEDIATRIC HEART NETWORK: SINGLE VENTRICLE RECONSTRUCTION EXTENSION STUDY BIOLOGIC SPECIMEN REPOSITORY FOR HYPOPLASTIC LEFT HEART SYNDROME AND OTHER SINGLE VENTRICLE ANOMALIES  
**Sponsor:** NIH - Subcontracts TO New England Research Institute U01 HL 068270  
**Project Dates and Amount of Award:** 07/01/08-08/31/11; \$192,718

**PI:** Shavit, Jordan  
**Title:** DECIPHERING THE GENETIC BASIS FOR CLINICAL HETEROGENEITY IN THROMBOPHILIA USING A ZEBRAFISH MODEL SYSTEM  
**Sponsor:** Hemophilia and Thrombosis Research Society (HTRS)  
**Project Dates and Amount of Award:** 07/01/08-06/30/10; \$150,000

**PI:** Van Mater, Heather  
**Title:** PRESCRIBING FOR CHILDREN WITH RHEUMATOLOGIC DISEASE: DIFFERENCES BETWEEN PEDIATRIC AND ADULT RHEUMATOLOGISTS  
**Sponsor:** Blue Cross Blue Shield of Michigan Foundation  
**Project Dates and Amount of Award:** 09/01/08-08/31/09; \$10,000

### Pharmacology

**PI:** Shewach, Donna  
**Co-I:** Soengas, Maria (Dermatology Department)  
**Title:** ONCOGENE C-MYC-DEPENDENT PATHWAYS IN CUTANEOUS MELANOMA  
**Sponsor:** NIH - Subcontracts TO Roswell Park Cancer Institute R01 CA 120244  
**Project Dates and Amount of Award:** 05/15/08-11/30/08; \$26,207

## Physical Medicine & Rehabilitation

**PI:** Hsu, Michael  
**Title:** NEUROBIOLOGICAL MECHANISMS BEHIND PAIN MODULATION IN SUBTYPES OF FIBROMYALGIA  
**Sponsor:** NIH - Subcontracts TO Albert Einstein Healthcare Network K12 HD 001097  
**Project Dates and Amount of Award:** 07/07/08-07/06/09; \$80,956

**PI:** Kirsch, Ned  
**Title:** ENVIRONMENTALLY APPROPRIATE BEHAVIORAL CUES FOR INDIVIDUALS WITH TRAUMATIC BRAIN INJURY  
**Sponsor:** Education, Department of-Subcontracts TO Institute for Matching Person and Technology  
**Project Dates and Amount of Award:** 11/01/07-10/31/08; \$31,689

## Psychiatry

**PI:** Brower, Kirk  
**Title:** 10TH ANNUAL ADDICTION PSYCHIATRY WORKSHOP UPDATE-2008  
**Sponsor:** Various Sponsors  
**Project Dates and Amount of Award:** 03/18/08-12/31/08; \$1,000

**PI:** Hanna, Gregory  
**Title:** ERROR-RELATED NEGATIVITY IN UNAFFECTED SIBLINGS OF YOUTH WITH OBSESSIVE-COMPULSIVE DISORDER  
**Sponsor:** Obsessive-Compulsive Foundation, Inc.  
**Project Dates and Amount of Award:** 07/15/08-07/14/09; \$63,161

**PI:** Kilbourne, Amy  
**Co-I:** Eisenberg, Daniel (Health Management and Policy) / Kim, Hyungjin (Ctr Statistical Consul & Res) / Milner, Karen (Psych Hospital & Community Svc)  
**Title:** IMPLEMENTING CHRONIC CARE MANAGEMENT FOR BIPOLAR DISORDER  
**Sponsor:** NIH 1 R01 MH 079994 01 A1  
**Project Dates and Amount of Award:** 09/19/08-05/31/13; \$3,431,634

**PI:** Liberzon, Israel  
**Co-I:** Aldridge, J (Neurology Department)  
**Title:** MEDIAL PREFRONTAL CORTEX AND HPA AXIS ROLES, IN GENERATION OF PTSD-LIKE, SYMPTOMS, IN SPS MODEL  
**Sponsor:** US DOD-Army, Department of the  
**Project Dates and Amount of Award:** 09/01/08-09/30/12; \$744,176

## Radiation Oncology

**PI:** Rehemtulla, Alnawaz  
**Co-I:** Bhojani, Mahaveer (Radiation Oncology - Ann Arbor) / Ross, Brian (Radiology Department)  
**Title:** HTS FOR FADD KINASE INHIBITORS USING MOLECULAR IMAGING  
**Sponsor:** NIH 1 R21 CA 131859 01 A1  
**Project Dates and Amount of Award:** 09/03/08-08/31/10; \$276,975

## Radiology

**PI:** Frey, Kirk  
**Co-I:** Adams, Lamell (Psychiatry Department) / Albin, Roger (Neurology Department) / Bohnen, Nicolaas (Radiology-Nuclear Medicine) / Chervin, Ronald (Neurology Department) / Gilman, Sid (Neurology Department) / Gilman, Sid (Psychiatry-Neuropsychology) / Giordani, Bruno (Psychiatry-Neuropsychology) / Kilbourn, Michael (Radiology-Nuclear Medicine) / Koeppe, Robert (Radiology-Nuclear Medicine) / Raffel, David (Radiology-Nuclear Medicine)  
**Title:** PET STUDY OF BIOCHEMISTRY AND METABOLISM OF THE CNS  
**Sponsor:** NIH 2 P01 NS 015655 26 A1  
**Project Dates and Amount of Award:** 09/15/08-06/30/13; \$6,354,007

**PI:** Parmar, Hemant  
**Co-I:** Mukherji, Suresh (Radiology Department) / Shirley, James (Radiology Department) / Srinivasan, Ashok (Radiology Department)  
**Title:** GADOBUTROL 1.0 MOLAR (GADOVIST) IN PATIENTS REFERRED FOR CONTRAST-ENHANCED MRI OF THE CENTRAL NERVOUS SYSTEM (CNS), A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO DETERMINE THE SAFETY AND EFFICACY OF  
**Sponsor:** Bayer Corporation  
**Project Dates and Amount of Award:** 07/28/08-01/27/10; \$119,800

**PI:** Sundaram, Baskaran  
**Co-I:** Kazerooni, Ella (Radiology Department) / Piert, Morand (Radiology-Nuclear Medicine)  
**Title:** RADIOFREQUENCY ABLATION IN HIGH-RISK PATIENTS WITH STAGE IA NON-SMALL CELL LUNG CANCER, A PILOT STUDY OF  
**Sponsor:** NIH - Subcontracts TO American College of Surgeons  
**Project Dates and Amount of Award:** 09/01/07-08/31/11; \$35,000

**PI:** Willatt, Jonathon  
**Co-I:** Dillman, Jonathan (Radiology Department)  
**Title:** COMPARISON OF CONTRAST-INDUCED NEPHROTOXICITY IN OUTPATIENTS FROM INTRAVENOUS OMPAQUE AND ISOVUE  
**Sponsor:** GE Healthcare  
**Project Dates and Amount of Award:** 07/01/08-06/30/10; \$387,269

## Surgery

**PI:** Dimick, Justin  
**Co-I:** Birkmeyer, John (General Surgery Section)  
**Title:** COMPOSITE MEASURES OF SURGICAL PERFORMANCE  
**Sponsor:** AHRQ 1 K08 HS 017765 01  
**Project Dates and Amount of Award:** 09/30/08-09/29/12; \$621,216

**PI:** Egeland, Brent  
**Title:** DEVELOPMENT OF A NOVEL BIOINTEGRATED PERIPHERAL NERVOUS SYSTEM INTERFACE  
**Sponsor:** Plastic Surgery Educational Foundation  
**Project Dates and Amount of Award:** 08/01/08-08/01/09; \$5,000

**PI:** Harake, Mazen  
**Title:** TISSUE ENGINEERING OF INCISIONAL HERNIA REPAIR USING ACELLULAR MYOFASCIAL CONSTRUCT  
**Sponsor:** Plastic Surgery Educational Foundation  
**Project Dates and Amount of Award:** 11/01/07-11/01/08; \$5,000

**PI:** Melvin, Melissa  
**Title:** THE INFLUENCE OF INNERVATION ON FIBER TYPE OF TISSUE-ENGINEERED MUSCLE  
**Sponsor:** Plastic Surgery Educational Foundation  
**Project Dates and Amount of Award:** 08/19/08-08/18/09; \$5,000

**PI:** Platt, Jeffrey  
**Title:** CARDIAC TRANSPLANTATION IN INFANCY  
**Sponsor:** NIH 7 P01 HL 079067 04  
**Project Dates and Amount of Award:** 09/15/08-06/30/10; \$2,609,378

**PI:** Simeone, Diane  
**Co-I:** Ljungman, Mats (Radiation Oncology - Ann Arbor) / Xu, Liang (Radiation Oncology - Ann Arbor)  
**Title:** ATDC FUNCTION IN HUMAN PANCREATIC ADENOCARCINOMA  
**Sponsor:** NIH 1 R01 CA 131045 01 A1  
**Project Dates and Amount of Award:** 09/01/08-07/31/12; \$1,272,888

## UMMS RESEARCH PUBLICATIONS

### Biological Chemistry

Abazeed ME, Fuller RS. Yeast Gga Proteins Are but AP-1 Is Not Required for Cell-Free Transport of Membrane Proteins from the Trans-Golgi Network to the Prevacuolar Compartment. *Mol Biol Cell*. 2008 Sep 10 (Epub ahead of print).

Damm KL, Ung PM, Quintero JJ, Gestwicki JE, Carlson HA. A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket. *Biopolymers*. 2008 Aug; 89(8): 643-52.

Falkner JA, Falkner JW, Yocum AK, Andrews PC. A Spectral Clustering Approach to MS/MS Identification of Post-Translational Modifications. *J Proteome Res*. 2008 Sep 19 (Epub ahead of print).

Franceschi RT, Ge C, Xiao G, Roca H, Jiang D. Transcriptional Regulation of Osteoblasts. *Cells Tissues Organs*. 2008 Aug 27 (Epub ahead of print).

Lipton AS, Heck RW, Hernick M, Fierke CA, Ellis PD. Residue ionization in LpxC directly observed by <sup>67</sup>Zn NMR spectroscopy. *J Am Chem Soc*. 2008 Sep 24; 130(38): 12671-9.

Marmorstein R, Trievel RC. Histone modifying enzymes: Structures, mechanisms, and specificities. *Biochim Biophys Acta*. 2008 Aug 3 (Epub ahead of print).

Nichols R, Egle JP, Langan NR, Palmer GC. The different effects of structurally related sulfakinins on *Drosophila melanogaster* odor preference and locomotion suggest involvement of distinct mechanisms. *Peptides*. 2008 Aug 22 (Epub ahead of print).

Ragsdale SW, Pierce E. Acetogenesis and the Wood-Ljungdahl pathway of CO<sub>2</sub> fixation. *Biochim Biophys Acta*. 2008 Aug 27 (Epub ahead of print).

Smith JL, Sherman DH. Biochemistry. An enzyme assembly line. *Science*. 2008 Sep 5; 321(5894): 1304-5.

Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. *J Clin Invest*. 2008 Sep 5 (Epub ahead of print).

Westphal NJ, Evans RT, Seasholtz AF. Novel expression of type 1 CRH receptor in multiple endocrine cell types in the murine anterior pituitary. *Endocrinology*. 2008 Sep 11 (Epub ahead of print).

Wu AM, Wu JH, Yang Z, Singh T, Goldstein IJ, Sharon N. Differential contributions of recognition factors of two plant lectins -Amaranthus caudatus lectin and Arachis hypogaea agglutinin, reacting with Thomsen-Friedenreich disaccharide (Galbeta1-3GalNAcalpha1-Ser/Thr). *Biochimie*. 2008 Sep 3 (Epub ahead of print).

Young Yu E, Wang F, Lei M, Lue NF. A proposed OB-fold with a protein-interaction surface in *Candida albicans* telomerase protein Est3. *Nat Struct Mol Biol*. 2008 Aug 24 (Epub ahead of print).

## Cell & Developmental Biology

Chapin R, Augustine-Rauch K, Beyer B, Daston G, Finnell R, Flynn T, Hunter S, Mirkes P, O'Shea KS, Piersma A, Sandler D, Vanparys P, Van Maele-Fabry G. State of the art in developmental toxicity screening methods and a way forward: a meeting report addressing embryonic stem cells, whole embryo culture, and zebrafish. *Birth Defects Res B Dev Reprod Toxicol*. 2008 Aug; 83(4): 446-56.

Noda D, Tsugu H, Nishikawa W, Shigekawa S, Fukushima T, Nabeshima K. [A case of idiopathic hypertrophic pachymeningitis presenting with hyperostosis] *No Shinkei Geka*. 2008 Aug; 36(8): 717-23. Japanese.

Oka Y, Asabe K, Shirakusa T, Nabeshima K. An antenatal appearance of megacystis-microcolon-intestinal hypoperistalsis syndrome. *Turk J Pediatr*. 2008 May-Jun; 50(3): 269-74.

Villa-Diaz LG, Pacut C, Slawny NA, Ding J, O'Shea KS, Smith GD. Analysis of the Factors That Limit the Ability of Feeder-Cells to Maintain the Undifferentiated State of Human Embryonic Stem Cells. *Stem Cells Dev*. 2008 Sep 2 (Epub ahead of print).

Zheng Y, Wildonger J, Ye B, Zhang Y, Kita A, Younger SH, Zimmerman S, Jan LY, Jan YN. Dynein is required for polarized dendritic transport and uniform microtubule orientation in axons. *Nat Cell Biol*. 2008 Aug 31 (Epub ahead of print).

## Family Medicine

Ellsworth JS, Collado B, Strawder T, Downey A, Ruffin MT, Djuric Z. Formulation of implementation intentions for improving fruit and vegetable intakes (Abstract). *J Am Diet Assoc*. 2008; 108(9 Suppl): A59.

Nease DE Jr, Ruffin MT 4th, Klinkman MS, Jimbo M, Braun TM, Underwood JM. Impact of a generalizable reminder system on colorectal cancer screening in diverse primary care practices: a report from the prompting and reminding at encounters for prevention project. *Med Care*. 2008 Sep; 46(9 Suppl 1): S68-73.

Paskett ED, Reeves KW, McLaughlin JM, Katz ML, McAlearney AS, Ruffin MT, Halbert CH, Merete C, Davis F, Gehlert S. Recruitment of minority and underserved populations in the United States: The centers for population health and health disparities experience. *Contemp Clin Trials*. 2008 Jul 31 (Epub ahead of print).

Richardson CR; STFM Research Committee. A new, dynamic resource for both students and teachers of family medicine: the Family Medicine Research wiki at FMDRL. *Ann Fam Med*. 2008 Sep-Oct; 6(5): 473.

Strath SJ, Holleman RG, Ronis DL, Swartz AM, Richardson CR. Objective physical activity accumulation in bouts and nonbouts and relation to markers of obesity in US adults. *Prev Chronic Dis*. 2008 Oct; 5(4): A131.

Wilkerson JE, Bailey JM, Bieniasz ME, Rock CL, Ruffin MT. Cervical cancer precursors, diet and bitter taste (6-n-propylthiouracil 'PROP') receptors. *Open Nutr*. 2008; 2: 51-3.

Zick SM, Djuric Z, Ruffin MT, Litzinger AJ, Normolle DP, Alrawi S, Feng MR, Brenner DE. Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. *Cancer Epidemiol Biomarkers Prev*. 2008 Aug; 17(8): 1930-6.

## Human Genetics

Charles MA, Mortensen AH, Potok MA, Camper SA. Pitx2 deletion in pituitary gonadotropes is compatible with gonadal development, puberty, and fertility. *Genesis*. 2008 Sep 18 (Epub ahead of print).

Chernin G, Heeringa SF, Gbadegesin R, Liu J, Hinkes BG, Vlangos CN, Vega-Warner V, Hildebrandt F. Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. *Pediatr Nephrol*. 2008 Sep; 23(9): 1455-60.

Fahim AT, Wang H, Feng J, Ginsburg D. Transgenic overexpression of a stable Plasminogen Activator Inhibitor-1 variant. *Thromb Res*. 2008 Sep 4 (Epub ahead of print).

Howell VM, de Haan G, Bergren S, Jones JM, Culiati CT, Michaud EJ, Frankel WN, Meisler MH. A Targeted Deleterious Allele of the Splicing Factor SCNMI in the Mouse. *Genetics*. 2008 Sep 14 (Epub ahead of print).

Lesperance MM, Burmeister M. Commentary on "Occupational Noise, Smoking and a High Body Mass Index are Risk Factors for Age-Related Hearing Impairment and Moderate Alcohol Consumption is Protective: a European Population-Based Multicentre Study" by Fransen et al., *J. Assoc. Res. Otolaryngol. J Assoc Res Otolaryngol*. 2008 Sep; 9(3): 261-3.

Patel JR, Brewer GJ. Age-related differences in Nf-kappaB translocation and Bcl-2/Bax ratio caused by TNFalpha and Abeta42 promote survival in middle-age neurons and death in old neurons. *Exp Neurol*. 2008 Sep; 213(1): 93-100.

Polydorides AD, Mukherjee B, Gruber SB, McKenna BJ, Appelman HD, Greenson JK. Adenoma-infiltrating Lymphocytes (AILs) are a Potential Marker of Hereditary Nonpolyposis Colorectal Cancer. *Am J Surg Pathol*. 2008 Aug 26 (Epub ahead of print).

Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, Krasnoselsky AL, Randolph TW, Omenn GS, Edelstein C, Barnett MJ, Thornquist MD, Goodman GE, Brenner DE, Feng Z, Hanash SM. Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera. *J Clin Oncol*. 2008 Sep 15 (Epub ahead of print).

Szpiech ZA, Jakobsson M, Rosenberg NA. ADZE: A rarefaction approach for counting alleles private to combinations of populations. *Bioinformatics*. 2008 Sep 8 (Epub ahead of print).

## Internal Medicine

### Infectious Diseases:

Aronoff DM, Peters-Golden M. Response to comment on "Misoprostol impairs female reproductive tract innate immunity against *Clostridium sordellii*". *J Immunol* 2008; 181(4): 2263-2264.

Nicolasora N, Cinti SK, Riddell J, Kauffman CA. A 53-year-old man with a large air bubble in his chest. Diagnosis: Bronchopleural fistula and hydropneumothorax caused by coccidioidomycosis (Photo Quiz). *Clin Infect Dis* 2008; 47(6): 823-824.

Simmon KE, Hall L, Woods CW, Marco F, Miro JM, Cabell C, Hoen B, Marin M, Utili R, Giannitsioti E, Doco-Lecompte T, Bradley S, Mirrett S, Tambic A, Ryan S, Gordon D, Jones P, Korman T, Wray D, Reller LB, Tripodi MF, Plesiat P, Morris AJ, Lang S, Murdoch DR, Petti CA. Phylogenetic analysis of viridans group streptococci causing endocarditis. *J Clin Microbiol* 2008; 46(9): 3087-3090.

## Microbiology and Immunology

Bauler LD, Duckett CS, O'Riordan MX. XIAP regulates cytosol-specific innate immunity to *Listeria* infection. *PLoS Pathog*. 2008 Aug 29; 4(8): e1000142.

Ding Y, Gruschow S, Greshock TJ, Finefield JM, Sherman DH, Williams RM. Detection of VM55599 and Preparaherquamide from *Aspergillus japonicus* and *Penicillium fellutanum*: Biosynthetic Implications. *J Nat Prod*. 2008 Aug 28 (Epub ahead of print).

Eaton KA. Diplomates day 2008. *Prim Dent Care*. 2008 Jul; 15(3): 102-4.

Himpsl SD, Lockett CV, Hebel JR, Johnson DE, Mobley HL. Identification of virulence determinants in uropathogenic *Proteus mirabilis* using signature-tagged mutagenesis. *J Med Microbiol*. 2008 Sep; 57(Pt 9): 1068-78.

Hogue IB, Bajaria SH, Fallert BA, Qin S, Reinhart TA, Kirschner DE. The dual role of dendritic cells in the immune response to human immunodeficiency virus type 1 infection. *J Gen Virol*. 2008 Sep; 89(Pt 9): 2228-39.

Laliberté J, Carruthers VB. Host cell manipulation by the human pathogen *Toxoplasma gondii*. *Cell Mol Life Sci*. 2008 Jun; 65(12): 1900-15. Review.

Lau HY, Huffnagle GB, Moore TA. Host and microbiota factors that control *Klebsiella pneumoniae* mucosal colonization in mice. *Microbes Infect*. 2008 Aug 13 (Epub ahead of print).

Nguyen Y, McGuffie BA, Anderson VE, Weinberg JB. Gammaherpesvirus modulation of mouse adenovirus type 1 pathogenesis. *Virology*. 2008 Sep 1 (Epub ahead of print).

Schaefer MR, Williams M, Kulpa DA, Blakely PK, Yaffee AQ, Collins KL. A novel trafficking signal within the HLA-C cytoplasmic tail allows regulated expression upon differentiation of macrophages. *J Immunol*. 2008 Jun 15; 180(12): 7804-17.

Simms AN, Mobley HL. PapX, a P Fimbrial Operon-Encoded Inhibitor of Motility in Uropathogenic *Escherichia coli*. *Infect Immun*. 2008 Aug 18 (Epub ahead of print).

Singh P, Yao Y, Weliver A, Broxmeyer HE, Hong SC, Chang CH. Vaccinia virus infection modulates the hematopoietic cell compartments in the bone marrow. *Stem Cells*. 2008 Apr; 26(4): 1009-16.

Smith JL, Sherman DH. Biochemistry. An enzyme assembly line. *Science*. 2008 Sep 5; 321(5894): 1304-5.

## Neurosurgery

Beltran S, Jacobs T. An excitatory path to unconsciousness: nonconvulsive status epilepticus. *Int Anesthesiol Clin*. 2008 Summer; 46(3): 159-70.

Ulgen BO, Brumblay H, Yang LJ, Doyle SM, Chung KC, Augusta Déjerine-Klumpke, M.D. (1859-1927): a historical perspective on Klumpke's palsy. *Neurosurgery*. 2008 Aug; 63(2): 359-66; discussion 366-7.

WINS White Paper Committee: Benzil DL, Abosch A, Germano I, Gilmer H, Maraire JN, Muraszko K, Pannullo S, Rosseau G, Schwartz L, Todor R, Ullman J, Zusman E. The future of neurosurgery: a white paper on the recruitment and retention of women in neurosurgery. *J Neurosurg*. 2008 Sep; 109(3): 378-86.

## Obstetrics & Gynecology

Delancey JO. Episiotomy: What's the angle? *Int J Gynecol Obstet*. 2008 Aug 20 (Epub ahead of print).

Harris LH. Second Trimester Abortion Provision: Breaking the Silence and Changing the Discourse. *Reproductive Health Matters*. 2008; 16(31 Supplement): 74-81.

Lankford JA, Haefner HK. Modification of the Ingram bicycle seat stool for the treatment of vaginal agenesis and stenosis. *Int J Gynecol Obstet*. 2008; 102: 301-303.

Nair AK, Young MA, Menon KMJ. Regulation of luteinizing hormone receptor mRNA expression by mevalonate kinase - role of the catalytic center in mRNA recognition. *FEBS Journal*. 2008; 275: 3397-3407.

## Ophthalmology & Visual Sciences

Banitt MR, Malta JB, Shtein RM, Soong HK. Delayed-onset isolated central Descemet membrane blister detachment following phacoemulsification. *J Cataract Refract Surg* 2008; 34(9): 1601-3.

Bian ZM, Elnor SG, Elnor VM. Regulated expression of truncated short variants of caspase-12 mRNA in human retinal pigment epithelial cells suggests their immunomodulating role. *Invest Ophthalmol Vis Sci*. 2008 (Epub ahead of print).

Chang B, Mandal MN, Chavali VR, Hawes NL, Khan NW, Hurd RE, Smith RS, Davisson ML, Kopplin L, Klein BE, Klein R, Iyengar SK, Heckenlively JR, Ayyagari R. Age-related retinal degeneration (arrd2) in a novel mouse model due to a nonsense mutation in the Mdm1 gene. *Hum Mol Genet*. 2008 (Epub ahead of print).

Demirci H, Marentette LJ, Nelson CC. The transglabellar/subcranial approach for surgical excision of periorbital second tumors in retinoblastoma. *Orbit* 2008; 27(4): 285-91.

Johnson MW. Etiology and Treatment of Macular Edema. *Am J Ophthalmol*. 2008 (Epub ahead of print).

Lucarelli MJ, Ahn HB, Kulkarni AD, Kahana A. Intratarsal epidermal inclusion cyst. *Ophthalm Plast Reconstr Surg* 2008; 24(5): 357-9.

Scott GR, Frueh BR, Flint A, Elnor VM. Fibrous dysplasia-like tumor of the lacrimal sac. *Ophthalm Plast Reconstr Surg* 2008; 24(5): 423-5.

Soong HK, Malta JB, Mian SI, Juhasz T. Femtosecond laser-assisted lamellar keratoplasty. *Arq Bras Oftalmol* 2008; 71(4): 601-6.

Trobe JD. 34th Annual North American Neuro-Ophthalmology Society (NANOS) Meeting, Orlando, Florida, March 8-13, 2008. *J Neuroophthalmol* 2008; 28(3): 255-60.

Van Meter WS, Musch DC, Jacobs DS, Kaufman SC, Reinhart WJ, Udell JJ. Safety of Overnight Orthokeratology for Myopia A Report by the American Academy of Ophthalmology. *Ophthalmology*. 2008 (Epub ahead of print).

## Orthopaedic Surgery

Doro LC, Hughes RE, Miller JD, Schultz KF, Hallstrom BR, Urquhart AG. The reliability of a kinematically-derived axis of the knee versus digitized anatomical landmarks using a knee navigation system. *The Open Biomedical Engineering Journal*. 2008; 2: 52-56.

## Otolaryngology

Lesperance MM, Burmeister M. Commentary on "Occupational Noise, Smoking and a High Body Mass Index are Risk Factors for Age-Related Hearing Impairment and Moderate Alcohol Consumption is Protective: a European Population-Based Multicentre Study" by Fransen et al., J. Assoc. Res. Otolaryngol. DOI 10.1007/s10162-008-0123-1. *J Assoc Res Otolaryngol*. 2008 Sep; 9(3): 261-3.

Pfingst BE, Burkholder-Juhasz RA, Zwolan TA, Xu L. Psychophysical assessment of stimulation sites in auditory prosthesis electrode arrays. *Hear Res* 2008 Aug; 242(1-2): 172-83.

Ruel J, Emery S, Nouvian R, Bersot T, Amilhon B, Van Rybroek JM, Rebillard G, Lenoir M, Eybalin M, Delprat B, Sivakumaran TA, Giros B, El Mestikawy S, Moser T, Smith RJ, Lesperance MM, Puel JL. Impairment of

SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice. *Am J Hum Genet*. 2008 Aug; 83(2): 278-92.

Xu L, Pfingst BE. Spectral and temporal cues for speech recognition: Implications for auditory prostheses. *Hear Res* 2008 Aug; 242(1-2): 132-40.

## Pathology

Bauler LD, Duckett CS, O'Riordan MX. XIAP regulates cytosol-specific innate immunity to *Listeria* infection. *PLoS Pathog*. 2008 Aug 29; 4(8): e1000142.

Bhan U, Trujillo G, Lyn-Kew K, Newstead MW, Zeng X, Hogaboam CM, Krieg AM, Standiford TJ. Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by *Legionella pneumophila*. *Infect Immun*. 2008 Jul; 76(7): 2895-904.

Buckland KF, O'Connor E, Murray LA, Hogaboam CM. Toll like receptor-2 modulates both innate and adaptive immune responses during chronic fungal asthma in mice. *Inflamm Res*. 2008 Aug; 57(8): 379-87.

Cao X, Nesvizhskii AI. Improved sequence tag generation method for Peptide identification in tandem mass spectrometry. *J Proteome Res*. 2008 Oct; 7(10): 4422-34.

Choi H, Fermin D, Nesvizhskii AI. Significance analysis of spectral count data in label-free shotgun proteomics. *Mol Cell Proteomics*. 2008 Jul 20 (Epub ahead of print).

Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. *Nat Med*. 2008 Aug; 14(8): 822-7.

Dressler GR. Another niche for Notch. *Kidney Int*. 2008 Jun; 73(11): 1207-9.

Dressler GR. Epigenetics, Development, and the Kidney. *J Am Soc Nephrol*. 2008 Aug 20 (Epub ahead of print).

Giordano TJ. Genome-wide studies in thyroid neoplasia. *Endocrinol Metab Clin North Am*. 2008 Jun; 37(2): 311-31, vii-viii. Review.

Goudreau M, D'Ambrosio LM, Kean MJ, Mullin M, Larsen BG, Sanchez A, Chaudhry S, Chen GI, Sichei F, Nesvizhskii AI, Aebersold R, Raught B, Gingras AC. A PP2A phosphatase high-density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. *Mol Cell Proteomics*. 2008 Sep 8 (Epub ahead of print).

Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG. Genetic changes of Wnt pathway genes are common events in metastatic carcinomas of the breast. *Clin Cancer Res*. 2008 Jul 1; 14(13): 4038-44.

Hess JL. What Hematopathology tells us about the Future of Pathology Informatics. *Archives of Pathology Laboratory Medicine*, 2008 (In press).

Hwang C, Oetjen KA, Kosoff D, Wojno KJ, Albertelli MA, Dunn RL, Robins DM, Cooney KA, Duckett CS. X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model. *Cell Death Differ*. 2008 May; 15(5): 831-40.

Ishii M, Hogaboam CM, Joshi A, Ito T, Fong DJ, Kunkel SL. CC chemokine receptor 4 modulates Toll-like receptor 9-mediated innate immunity and signaling. *Eur J Immunol*. 2008 Aug; 38(8): 2290-302.

Kallal LE, Lukacs NW. The role of chemokines in virus-associated asthma exacerbations. *Curr Allergy Asthma Rep*. 2008 Sep; 8(5): 443-50.

Lindell DM, Berlin AA, Schaller MA, Lukacs NW. B cell antigen presentation promotes Th2 responses and immunopathology during chronic allergic lung disease. *PLoS ONE*. 2008 Sep 3; 3(9): e3129.

Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. *Eur J Immunol*. 2008 Aug; 38(8): 2168-79.

Lukacs NW, Berlin AA, Franz-Bacon K, Sasik R, Sprague LJ, Ly TW, Hardiman G, Boehme SA, Bacon KB. CRTH2 antagonism significantly ameliorates airways hyperreactivity, and down-regulates inflammation-induced genes in a mouse model of airway inflammation. *Am J Physiol Lung Cell Mol Physiol*. 2008 Aug 29 (Epub ahead of print).

Lukacs NW, Smit JJ, Schaller MA, Lindell DM. Regulation of immunity to respiratory syncytial virus by dendritic cells, toll-like receptors, and notch. *Viral Immunol*. 2008 Jun; 21(2): 115-22. Review.

Marelli M, Nesvizhskii AI, Aitchison JD. Identifying bona fide components of an organelle by isotope-coded labeling of subcellular fractions: an example in peroxisomes. *Methods Mol Biol*. 2008; 432: 357-71.

Meneghin A, Choi ES, Evanoff HL, Kunkel SL, Martinez FJ, Flaherty KR, Toews GB, Hogaboam CM. TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. *Histochem Cell Biol*. 2008 Jul 17 (Epub ahead of print).

Muntean AG, Giannol D, Udager A, Hess JL. The PHD fingers of MLL block MLL fusion protein-mediated transformation. *Blood*. 2008 (In press).

Trujillo G, O'Connor EC, Kunkel SL, Hogaboam CM. A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis. *Am J Pathol*. 2008 May; 172(5): 1209-21.

Whiteman EL, Liu CJ, Fearon ER, Margolis B. The transcription factor snail represses Crumbs3 expression and disrupts apico-basal polarity complexes. *Oncogene*. 2008 Jun 19; 27(27): 3875-9.

Zhuang D, Mannava S, Grachtchouk V, Tang WH, Patil S, Wawrzyniak JA, Berman AE, Giordano TJ, Prochowik EV, Soengas MS, Nikiforov MA. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. *Oncogene*. 2008 Aug 4 (Epub ahead of print).

## **Pediatrics & Communicable Diseases**

Armstrong MB, Schumacher KR, Mody R, Yanik GA, Pipari AW Jr, Castle VP. Bortezomib as a therapeutic candidate for neuroblastoma. *J Exp Ther Oncol* 2008; 7(2): 135-45.

Boxer LA. Introduction of the American Pediatric Society's 2008 John Howland award recipient, Richard B. Johnston, Jr., M.D. *Pediatr Res* 2008 Sep; 64(3): 317-9.

Dempsey AF, Cowan AE, Stokley S, Messonnier M, Clark SJ, Davis MM. The role of economic information in decision-making by the Advisory Committee on Immunization Practices. *Vaccine*. 2008 Aug 15 (Epub ahead of print).

Donn SM. Keeping watch. Neonatal pulmonary graphics enhance safety and efficacy of mechanical ventilation. *Advance for Managers of Respiratory Care*. 2008; 17: 22-25.

Donn SM, Sinha SK. Pulmonary surfactant use in the preterm infant – an update. *US Respiratory Disease* 2008: 30-32.

Gilmont RR, Somara S, Bitar KN. VIP induces PKA-mediated rapid and sustained phosphorylation of HSP 20. *Biochem Biophys Res Commun*. 2008 Aug 24 (Epub ahead of print).

Hanauer DA, Rhodes DR, Chinnaiyan AM. Identifying significant associations using free text problem summary lists in a clinical data repository. *AMIA Annu Symp Proc*. 2007 Oct 11: 968.

Kaul DR, Lowe L, Visvesvara GS, Farnen S, Khaled YA, Yanik GA. Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriniconazole. *Transpl Infect Dis*. 2008 Aug 13 (Epub ahead of print).

Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). *Biol Blood Marrow Transplant*. 2008 Sep; 14(9): 1017-21.

Nguyen TC, Han YY, Kiss JE, Hall MW, Hassett AC, Jaffe R, Orr RA, Janosky J, Carcillo JA. Intensive plasma exchange increases ADAMTS-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. *Crit Care Med*. 2008 Aug 28 (Epub ahead of print).

Nguyen Y, McGuffie BA, Anderson VE, Weinberg JB. Gammaherpesvirus modulation of mouse adenovirus type 1 pathogenesis. *Virology*. 2008 Sep 1 (Epub ahead of print).

Peterson CC, Johnson CE, Ramirez LY, Huestis S, Pai AL, Demaree HA, Drotar D. A meta analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. *Pediatric Blood and Cancer*. 2008 Jul; 51: 99-104.

Sarkar S, Dechert RE, Becker MA, Attar MA, Schumacher RE, Donn SM. Double-masked, randomized, placebo-controlled trial of furosemide after packed red blood cell transfusion in preterm infants. *J Neonatal Perinatal Med*. 2008; 1: 13-19.

Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL. HIV-1 Nef targets MHC-1 and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. *PLoS Pathog*. 2008 Aug 22; 4(8): e1000131.

Sinha S, Gupta S, Donn SM. Immediate respiratory management of the preterm infant. *Semin Fetal Neonatal Med*. 2008; 13: 24-29.

Sinha SK, Donn SM. Lucinactant in neonatal respiratory distress syndrome: an evidence-based review of its effectiveness on clinical outcomes. *Core Evidence* 2008: 233-240.

Vartanian R, Donn SM. Neonatal diabetes: applying molecular biology to patient care. *Curr Pediatr Rev*, 2008; 4: 80-83.

Yoon EY, Freed GL. The need for and creation of a comprehensive pediatric research network. *Paediatr Drugs*; 2008; 10(5): 279-80.

Yu C, Hanauer DA, Jagadish HV, States DJ. Simplifying access to a Clinical Data Repository using schema summarization. *AMIA Annu Symp Proc*. 2007 Oct 11: 1163.

## **Pharmacology**

Benninger RK, Zhang M, Head WS, Satin LS, Piston DW. Gap Junction Coupling and Calcium Waves in the Pancreatic Islet. *Biophys J*. 2008 Sep 19 (Epub ahead of print).

Blazer LL, Neubig RR. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. *Neuropsychopharmacology*. 2008 Sep 17 (Epub ahead of print).

Booth EA, Flint RR, Lucas KL, Knittel AK, Lucchesi BR. Estrogen protects the heart from ischemia-reperfusion injury via COX-2-derived PG12. *J Cardiovasc Pharmacol*. 2008 Sep; 52(3): 228-35.

Booth EA, Lucchesi BR. Estrogen-mediated protection in myocardial ischemia-reperfusion injury. *Cardiovasc Toxicol*. 2008; 8(3): 101-13.

Brackenbury WJ, Isom LL. Voltage-gated Na<sup>+</sup> channels: Potential for b subunits as therapeutic targets. *Expert Opinion on Therapeutic Targets*. 2008 Sep 12: 1191-203.

Carbone LD, Simpson RU, Weber KT. Vitamin D and calcium dyshomeostasis associated heart failure. *Heart*. 2008, 94(5): 540-3.

Cavero I, Kaplan, HR. Drug Discovery paradigms: past, present, future – A centennial symposium of the American Society for Pharmacology and Experimental Therapeutics. *Expert Opin. Drug Discov*. 2008; 3(9): 1145–1154.

Hollenberg PF, Kent UM, Bumpus NN. Mechanism-based inactivation of human cytochromes P450s: Experimental characterization, reactive intermediates, and clinical implications. *Chem. Res. Toxicol*. 2008; 21: 189-205.

Huang X, Charbeneau RA, Fu Y, Kaur K, Gerin I, MacDougald OA, Neubig RR. Resistance to diet-induced obesity and improved insulin sensitivity in mice with a regulator of G protein signaling-insensitive G184S Gnai2 allele. *Diabetes*. 2008; 57(1): 77-8.

Lin H-I, Myshkin E, Waskell L, Hollenberg PF. Peroxynitrite inactivation of human cytochrome P450s 2B6 and 2E1: Heme modification and site-specific nitrotyrosine formation. *Chem. Res. Toxicol*. 2007 Oct; 20: 1612-1622.

Lutz S, Shankaranarayanan A, Coco C, Nance M, Vettel C, Baltus D, Evelyn C, Neubig R, Wieland T, Tesmer JGG. Structure of Gαq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. *Science*, 2007; 318: 1923-7.

Mancuso PA, Rahman A, Dandu L, Hershey SD, Simpson RU. 1,25-Dihydroxyvitamin D treatment of the spontaneous hypertensive heart failure prone rat [SHHF]: Leptin and cardiac hypertrophy. *J Cardiovascular Pharmacology*, 2008 Jun; 51(6): 559-64.

Neubig RR. And the winner is...RGS4! *Circ. Res*. 2008 Aug. 29; 103(5): 444-6.

Pei J, Dishinger JF, Roman DL, Rungwanitcha C, Neubig RR, Kennedy RT. Microfabricated Channel Array Electrophoresis for Characterization and Screening of Enzymes Using RGS-G Protein Interactions as a Model System. *Anal Chem*. 2008 Jul 1; 80(13): 5225-31.

Roof RA, Sobczyk-Kojiro K, Turbiak AJ, Roman DL, Pogozheva ID, Blazer LL, Neubig RR\*, Mosberg HI\*. (These authors contributed equally to this work.) Novel Peptide Ligands of RGS4 from a One-Bead, One-Compound Library. *Chemical Biology and Drug Discovery*, 2008 Aug; 72(2): 111-9.

Singh P, Wang B, Madea T, Palczewski K, Tesmer JGG. Structures of rhodopsin kinase in different ligand states reveal key elements involved in G protein-coupled receptor kinase activation. *J. Biol.Chem*. 2008; 283: 14053-62.

Tian Y, Corkey RF, Yaney GC, Goforth PB, Satin LS, Moitoso de Vargas L. Differential modulation of L-type calcium channel subunits by oleate. *Am J Physiol Endocrinol Metab*. 2008 Jun; 294(6): E1178-86.

Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU. Functional vitamin D receptor in the f-tubules of cardiac myocytes. *Endocrinology* 2008; 149(2): 558-564.

Zhang M, Fendler B, Peercy B, Goel P, Bertram R, Sherman AS, Satin LS. Long lasting synchronization of calcium oscillations by cholinergic stimulation in isolated pancreatic islets. *Biophys J*. 2008 Aug 15 (Epub ahead of print).

## **Physical Medicine & Rehabilitation**

Hernandez ME, Murphy SL, Alexander NB. Characteristics of older adults with self-reported stooping, crouching, or kneeling difficulty. *J Gerontol A Biol Sci Med Sci*. 2008 Jul; 63(7): 759-63.

Murphy SL, Gretebeck KA, Alexander NB. The bath environment, the bathing task, and the older adult: a review and future directions for bathing disability research. *Disabil Rehabil*. 2007 Jul 30; 29(14): 1067-75. Review.

Murphy SL, Nyquist LV, Strasburg DM, Alexander NB. Bath transfers in older adult congregate housing residents: assessing the person-environment interaction. *J Am Geriatr Soc.* 2006 Aug; 54(8): 1265-70.

Murphy SL, Smith DM, Alexander NB. Measuring activity pacing in women with lower-extremity osteoarthritis: a pilot study. *Am J Occup Ther.* 2008 May-Jun; 62(3): 329-34.

Murphy SL, Smith DM, Clauw DJ, Alexander NB. The impact of momentary pain and fatigue on physical activity in women with osteoarthritis. *Arthritis Rheum.* 2008 Jun 15; 59(6): 849-56.

Murphy SL, Strasburg DM, Lyden AK, Smith DM, Koliba JF, Dadabhoy DP, Wallis S. Effects of activity strategy training on pain and physical activity in older adults with knee or hip osteoarthritis. *Arthritis Rheum.* 2008 (In press).

## Psychiatry

Bernstein A, Trafton J, Ilgen M, Zvolensky MJ. An evaluation of the role of smoking context on a biobehavioral index of distress tolerance. *Addict Behav.* 2008 Nov; 33(11): 1409-15.

Burnette ML, Ilgen M, Frayne SM, Lucas E, Mayo J, Weitlauf JC. Violence perpetration and childhood abuse among men and women in substance abuse treatment. *J Subst Abuse Treat.* 2008 Sep; 35(2): 217-22.

Cardasis W, Huth-Bocks A, Silk, KR. Tattoos and antisocial personality disorder. *Personality Ment Health* 2008; 2: 171-182.

Chermack ST, Murray RL, Walton MA, Booth BA, Wrybeck J, Blow FC. Partner aggression among men and women in substance use disorder treatment: Correlates of psychological and physical aggression and injury. *Drug Alcohol Depend.* 2008 Nov 1; 98(1-2): 35-44.

Ilgen MA, Hu KU, Moos RH, McKellar J. Continuing care after inpatient psychiatric treatment for patients with psychiatric and substance use disorders. *Psychiatr Serv.* 2008 Sep; 59(9): 982-8.

Ilgen M, Jain A, Kim HM, Trafton JA. The effect of stress on craving for methadone depends on the timing of last methadone dose. *Behav Res Ther.* 2008 Oct; 46(10): 1170-1175.

Kilbourne AM, Irmiter C, Capobianco J, Reynolds K, Milner K, Barry K, Blow FC. Improving Integrated General Medical and Mental Health Services in Community-based Practices. *Adm Policy Ment Health.* 2008 Sep; 35(5): 337-45.

Kilbourne AM, Welsh D, McCarthy JF, Post EP, Blow FC. Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders. *J Gen Intern Med.* 2008 Oct; 23(10): 1628-33.

Klykylo K, Klykylo W. Managing Attention Deficit Hyperactivity Disorder in the Emergency Department. *Psychiatry* 2008 Aug; 5(8): 43-47.

Lee I, Majoros IJ, Williams CR, Athey BD, Baker JR Jr. Interactive design strategy for a multi-functional PAMAM dendrimer-based nanotherapeutic using computational models and experimental analysis. *J. Comput. Theor. NanoSci.* 2008; 6(1): 1-7.

Perron BE, Alexander-Eitzman B, Gillespie DF, Pollio D. Modeling the mental health effects of victimization among homeless persons. *Soc Sci Med.* 2008 Nov; 67(9): 1475-9.

Wojnar M, Ilgen MA, Jakubczyk A, Wnorowska A, Klimkiewicz A, Brower KJ. Impulsive suicide attempts predict post-treatment relapse in alcohol-dependent patients. *Drug Alcohol Depend.* 2008 Oct 1; 97(3): 268-75.

## Radiation Oncology

Dorfman GS, Lawrence TS, Matrisian LM; Translational Research Working Group. The Translational Research Working Group developmental pathway for interventional devices. *Clin Cancer Res.* 2008 Sep 15; 14(18): 5700-6.

Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. *J Clin Oncol.* 2008 Sep 10; 26(26): 4333-9.

Soto DE, Daignault S, Sandler HM, Ray ME. No Effect of Statins on Biochemical Outcomes After Radiotherapy for Localized Prostate Cancer. *Urology.* 2008 Aug 21 (Epub ahead of print).

Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J, Kresel JJ, Curran WJ, Diaz A, Mehta MP. Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03. *Int J Radiat Oncol Biol Phys.* 2008 Aug 22 (Epub ahead of print).

Zheng M, Morgan-Lappe S, Yang J, Bockbrader K, Pamarthy D, Thomas D, Fesik S, Sun Y. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. *Cancer Res.* 2008 Sep 15; 68(18): 7570-8.

## Surgery

### General Surgery:

Balin SJ, Platt JL, Cascalho M. New insights into the functions of B cells. *Pediatr Transplant.* 2008; 12: 510-515.

Bartosh SM, Ryckman FC, Shaddy R, Michaels MG, Platt JL, Sweet SC. A national conference to determine research priorities in pediatric solid organ transplantation. *Pediatr Transplant.* 2008; 12: 153-166.

Lynch RJ, Platt JL. Accommodation in organ transplantation. *Curr Opin Organ Transplant.* 2008; 13: 165-170.

### Pediatric Surgery:

Koga, H, Yang, H, Haxhija, EQ, Teitelbaum, DH. The role of Angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse model. *Pediatr Surg Intern.* 2008 (Accepted).

Yang, H, Feng, Y, Sun, X, Teitelbaum, DH. Enteral versus Parenteral Nutrition: Effect on Intestinal Barrier Function. *Annals of the New York Academy of Sciences.* 2008 (Accepted).

## Urology

Gilbert SM, Montie JE. Determining when to recommend continent urinary diversion. *Can Urol Assoc J.* 2008 Aug; 2(4): 407-9.

Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. *Cancer Res.* 2008 Sep 15; 68(18): 7629-37.

Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT. Lymphovascular Invasion of Urothelial Cancer in Matched Transurethral Bladder Tumor Resection and Radical Cystectomy Specimens. *J Urol.* 2008 Sep 16 (Epub ahead of print).

Liao J, Li X, Koh AJ, Berry JE, Thudi N, Rosol TJ, Pienta KJ, McCauley LK. Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. *Int J Cancer.* 2008 Aug 26; 123(10): 2267-2278.

Mizutaniab K, Pienta KJ. Re: RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastasis model. *Eur Urol.* 2008 Sep; 54(3): 688.

Montie JE. Screen detected, low volume prostate cancer: The case for active treatment. *Urol Oncol.* 2008 Sep-Oct; 26(5): 511-5.

Roca H, Varsos ZS, Mizutani K, Pienta KJ. CCL2, survivin and autophagy: New links with implications in human cancer. *Autophagy.* 2008 Oct 1; 4(7): 969-71.

Schulte RT, Wood DP, Daignault S, Shah RB, Wei JT. Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations after radical prostatectomy. *Cancer.* 2008 Aug 22; 113(7): 1559-1565.

Soto DE, Daignault S, Sandler HM, Ray ME. No Effect of Statins on Biochemical Outcomes After Radiotherapy for Localized Prostate Cancer. *Urology.* 2008 Aug 21 (Epub ahead of print).

Wallner LP, Clemens JQ, Sarma AV. Prevalence of and risk factors for prostatitis in African American men: The Flint Men's Health Study. *Prostate.* 2008 Sep 18 (Epub ahead of print).

Woods Ignatoski KM, Grewal NK, Markwart SM, Vellaichamy A, Chinnaiyan AM, Yeung K, Ray ME, Keller ET. Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. *Int J Radiat Oncol Biol Phys.* 2008 Sep 1; 72(1): 153-60.